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ABSTRACT 
Magnetic nanoparticles (MNPs) are currently being extensively studied in 
multitude of biomedical applications because of their exceptional biocompatibility. By 
attaching different targeting ligands/molecules, MNPs have been broadly used in 
magnetic hyperthermia, cancer therapy, targeted drug delivery, MRI imaging, pathogen 
detection, and biological cell-separation. In this dissertation, MNPs coated with 
polyethylene oxide (PEO) based polymer (PEO-MNPs) and functionalized with bacterial 
adhesin-specific glycoconjugate molecule Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp (GM3-
MNPs), are investigated for their interactions with enterotoxigenic Escherichia coli (E. 
coli). It also describes the feasibility of using alternating magnetic fields (AMF) for 
targeted killing of E. coli K99 (EC K99) strain using MNPs. Lastly, the interactions of 
MNPs with normal human colon cells CCD-18Co are explored to assess their in vitro 
biocompatibility.  
First, GM3-MNPs were synthesized via 'click chemistry' platform. Specific 
aggregation of EC K99 was seen due to interactions occurring between GM3-MNPs and 
adhesin molecules of EC K99. These interactions were observed by means of 
fluorescence microscopy, transmission electron microscopy (TEM), and colony forming 
units (CFU) assays. The preliminary cytotoxicity assay performed on normal colon cells 
CCD-18Co indicated excellent biocompatibility of GM3-MNPs. Thus, such
glycoconjugate-functionalized MNPs can be effectively utilized as anti-adhesion and 
anti-bacterial agents for reducing gastro-intestinal (GI) tract infections.  
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Next, GM3-MNPs were used along with AMF for targeted killing of EC K99 
cells. CFU/ml assays indicated that killing rate of EC K99 was mainly dependent on 
concentration of GM3-MNPs and AMF exposure time. Clinically relevant reduction in 
CFU/ml of EC K99 was achieved after 120 minutes of AMF exposure in presence of 
GM3-MNPs in both pure and mixed bacterial culture environment. Extensive cell-
membrane damage was observed via fluorescence microscopy and TEM imaging of EC 
K99 cells after AMF exposure in presence of GM3-MNPs. AMF exposure in presence of 
GM3-MNPs also caused significant decrease in intracellular ATP levels of EC K99. 
These results suggest that bacterial specific glycoconjugate MNPs along with AMF can 
be efficiently employed as novel non-antibiotic platform to inactivate targeted bacterial 
pathogens. 
Finally, the overall biocompatibility of GM3-MNPs was examined in CCD-18Co 
cells and compared to that of PEO-MNPs. GM3-MNPs were found to have relatively 
stable hydrodynamic diameter in cell-culture media DMEM whereas PEO-MNPs 
drastically increased their size on account of protein-corona formation. Both cytotoxicity 
and ATP assays revealed that GM3-MNPs exhibited great biocompatibility in the cells. 
CCD-18Co cells also maintained their overall cell-membrane integrity in the presence of
GM3-MNPs. Interestingly, GM3-MNPs were able to substantially decrease the 
glutathione (GSH) levels in the cells leading to increased oxidative stress. Thus, by 
properly controlling surface properties of glycoconjugate functionalized MNPs and 
attaching different drugs, they can be potentially used as colon specific drug-delivery 
carriers for therapeutic applications. 
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Antibiotic Resistance in Bacteria 
Currently, there are more than 160 different kinds on antibiotics available for 
therapeutic purposes [1]. However, unrestricted and prolonged usage of antibiotics has 
resulted in rapid emergence of new strains of microorganisms that have developed 
resistance to these drugs and over a period of time they have evolved as multi-drug 
resistant microorganisms. For example, the first penicillin-resistant strain of 
Streptococcus pneumoniae was observed in USA in 1974 in a patient suffering from 
pneumococcal meningitis [2]. Methicillin resistant Staphylococcus aureus (MRSA) and 
vancomycin resistant Enterococci (VRE) were first identified in the 1960s [3] and in the 
mid-1980s [4] respectively. Some of the mechanisms commonly found in these 
antibiotic-resistant pathogens are alteration of drug target, degradation of drugs by 
producing enzymes, changes in target accessibility and increased drug efflux [5] (Figure 
1.1). According to a recent report by CDC, approximately 2 million people in the US 
have illnesses related to antibiotic resistant infections and each year at least 23,000 deaths 
occur as a result of such infections [6]. Given the fact that developing new antibiotics is a 
slow and costly affair, there is an urgent need to treat such infections by employing 
therapies that do not require the traditional usage of antibiotics [7-9].  
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Figure 1.1 Different mechanisms employed by bacteria to render antibiotic useless. Reprinted from [5] - Reproduced 
with permission from Nature Publishing Group. 
 
Role of Adhesin in Bacterial Attachment and Pathogenesis 
Pathogen attachment is a very complex phenomenon and a vital process to initiate 
infection in the host-cell. The microorganisms have to initially colonize themselves onto 
the host-cell surfaces and grow in sufficient numbers in short span of time to produce 
clinical symptoms [10, 11]. Bacterial pathogens typically target animal or human host by 
attaching onto epithelial and mucosal surfaces of respiratory tract, gastrointestinal tract 
and genitourinary tract [12]. Bacterial adhesion is essential since pathogens have to 
overcome different nonspecific defense mechanisms like sneezing and fluid flow 
occurring in the host. Adhesion also enables the pathogen to utilize host-cell nutrients in 
order to multiply rapidly along with enabling the pathogen to deliver toxin in the host-cell 
and ultimately penetrating into the host tissue [13].  
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Bacterial pathogens utilize two primary mechanisms to adhere onto host cells, 
namely carbohydrate-protein recognition and protein-protein interaction [14]. Most of the 
studies to understand adhesion mechanisms are done by linking carbohydrate-protein 
recognition process since it is very difficult to elucidate the protein-protein interaction on 
account of protein instability and its changing conformations [15]. The carbohydrate-
protein interaction that binds bacterial pathogens onto the host-cell tissue are mediated by 
specialized structures called adhesin/fimbriae, which have lectin proteins and are located 
on the microbial surface. Fimbriae are typically expressed by almost every gram-negative 
bacterial species that has been studied [16]. It should be however noted that bacterial 
adhesion mediated by fimbriae is a highly specific phenomenon. The adhesion structures 
have a high degree of preference for a particular host-cell tissue. For example, E. coli 
usually colonizes GI tract whereas Streptococci colonize the skin and esophagus in 
humans [17]. Several comparative studies have been done to address the species 
specificity of bacterial adhesins for a particular type of host-cell receptor [14].  
 
Biological Importance of Carbohydrates in Pathogenesis 
It was only in the early 1990s that carbohydrates were recognized as important 
biomolecules, which had great diversity, and thereby carbohydrate molecules were 
explored for finding their applications in medical and pharmaceutical industries [18]. 
Apart from their roles in cell metabolism, carbohydrates play an important role in various 
biological processes like inflammation [19], cancer metastasis [20] and cell-signaling to 
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name a few. They also play modulatory role in hormone signaling and typically act as 
receptor molecules for attachment of antibodies, proteins and other biomolecules [19].   
Adherence of pathogens onto host-cell is one of earlier events that can trigger the onset of 
infection. The binding affinity of a single carbohydrate-protein interaction is generally 
weak on account of monovalency. However, multiple interactions between the 
carbohydrate molecule and its respective protein result in polyvalency, which greatly 
enhances the binding capacity and thereby aids in the adherence process [21, 22]. By 
taking advantage of these multiple adherence factors, a large number of bacteria, their 
toxins, and viruses are able to gain entry into the host-cell and exert their harmful effects 
on the host-cell.  
The adhesion process of bacteria attaching onto the host-cell is complex in nature. 
This attachment is mediated by bacterial lectins that are present on their surface. These 
lectins, generally in the form of fimbriae, recognize specific glycolipid or glycoprotein 
receptors present on the host-cell surface [23]. E. coli is one such enteropathogen that 
expresses different types of pili e.g., Type-1 pili, P-type fimbriae, S-type fimbriae, etc. 




Table 1.1: Receptor specificity of bacterial fimbriae. Modified from [24]. Reproduced with permission from Elsevier 
Ltd. 
 
Apart from bacterial pathogens, their toxins and even viruses have been shown to 
bind to specific carbohydrate molecules. The viral protein hemagglutinin has been shown 
to bind to host-cell N-Acetylneuraminic acid and this interaction has been found to be 
polyvalent in nature [22]. Similarly, other viruses like rotavirus and Sendai virus have 
been found to attach to specific carbohydrate ligands [22]. Clinically important bacterial 
pathogens like enterotoxigenic E. coli, Vibrio cholera, Shigella dysenteriae all produces 
lethal toxins which are responsible for causing diseases ranging from mild diarrhea to 
lethal toxic shock induced death in humans. These toxins are able to exert their toxic 
effects by entering the host-cell after binding to their carbohydrate receptors. It has been 
found that cholera toxin and heat-labile enterotoxin attach themselves onto the luminal 
side of the intestinal epithelium by binding to GM1 gangliosides [25]. The Shiga-like 
toxins have been found to bind onto the host-cell receptors through Gb3 ceramide 
glycolipids [26, 27]. 
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Enterotoxigenic Escherichia coli 
E. coli is one of the most common types of bacteria naturally occurring in the 
digestive tract of humans and animals. While most of the E. coli strains are harmless to 
humans and animals, there are few E. coli serogroups that are mainly responsible in 
causing bacterial infection. These strains typically tend to be host-specific. The 
prevalence of the serogroups and presence of adhesins are considered to be the primary 
factors that facilitate intestinal colonization of E. coli. Based on different serological 
features, enteric E. coli have been classified into 5 different groups: 1) Enterotoxigenic E. 
coli (ETEC), 2) Enteropathogenic E. coli (EPEC), 3) Enteroinvasive E. coli (EIEC), 4) 
Enterohemorrhagic E. coli (EHEC), and 5) Enteroaggregative E. coli (EAEC) [28]. The 
production of different types of toxins by these serovar groups is considered to play very 
crucial role in producing clinical signs of infection. E. coli belonging to the ETEC group 
is responsible for causing traveler’s diarrhea in humans and bloody diarrhea in neonatal 
calves, pigs and lambs [29]. Though enough reports have cemented the importance of 
adhesins in the overall process of infection caused by E. coli in humans, few studies have 
been conducted to understand the pathogenesis of ETEC strains in farm animals. ETEC 
adhere to small intestinal microvilli membranes in vivo via adhesins and produce 
enterotoxins that act on enterocytes and thereby causing diarrhea [30]. Recently, 
numerous studies have reported an increase in multi-drug resistance of this strain 
associated with antibiotic treated animal feed [31-34]. E. coli K99 is the main causative 
agent of bloody diarrhea in young calves, lambs and pigs, a condition also known as 
colibacillosis [35]. The disease typically affects newborn animals within 2-3 weeks of 
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birth. This strain bears K99 antigen which also acts as fimbriae and adheres the bacterium 
onto the ileal villus epithelium of calf and pigs [36-39]. E. coli K99 strain specifically 
attaches to small intestinal mucus and recognizes sialic acid derivatives present on 
glycolipid receptors [40]. Experimental studies have shown that glycoprotein glycans 
isolated from bovine plasma inhibited the fimbriae specific adherence of E. coli K99 to 
mucus glycoproteins [41]. Oral administration of these glycans protected young calves 
from the infection and reduced the number of bacteria present in small intestine mucus by 
100 folds. This showed that such glycans could effectively act as anti-adhesive 
molecules, which can prevent colibacillosis in young farm animals.  
 
Role of Carbohydrates in Anti-adhesion Therapy 
It was not until 1990s that the concept of using carbohydrates as natural anti-
adhesive agents came into limelight. The need for finding new strategies in order to 
combat the growing concern of antibiotic-resistant strains of microorganisms, aided the 
research in glycol-biology field with special focus in microbiological context. Several 
studies were carried out in this aspect and showed the feasibility of carbohydrates as an 
alternative to conventional antibiotic treatment [42-44]. The concept of using 
carbohydrates as new anti-adhesion agents is mainly based upon the following 
hypotheses: 1) Microbial infection is initiated due to binding of the pathogen onto the 
host-cell and 2) Anti-adhesive agents must either interfere with the binding of pathogen 
to the host or help in detachment of microbes from the host tissues during early stages of 
infection [13, 45]. Since these anti-adhesive agents interfere with adhesin-host-cell 
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receptor (proteins) interactions, it would be much easier to develop analogues that 
interact with carbohydrate receptors as it is difficult to elucidate the exact protein 
structure [44].  
Numerous natural carbohydrates and synthetic glycoconjugates have been used to 
understand this mechanism of anti-adhesion in bacteria and viruses [43, 46, 47]. Since 
synthetic glycoconjugates typically have low binding affinity, they can be used as 
polymers, dendrimers and liposomes in order to attain multivalency and achieve effective 
high affinity and inhibitory effect against various carbohydrate receptors and this has 
been shown in both in vitro and in vivo studies [48, 49].  
 
Role of Carbohydrate Functionalized Nanomaterials in Pathogen 
Detection 
Rapid, sensitive and reliable methods for detection of microorganisms hold the 
key for accurate diagnosis of infectious diseases. Conventional techniques commonly 
used for this purpose include culture and colony counting, polymerase chain reaction and 
immunological assays [50-53]. However, these approaches are laborious, time-
consuming and having low sensitivity thresh-hold levels. Moreover, you encounter 
numerous false-negative results by using the above-mentioned conventional methods. It 
is in this context that the use of nanomaterials has provided a great impetus for rapid and 
accurate detection of microbial pathogens in food and clinical samples. These 
nanomaterials can act as unique nano-biosensor for specific detection of complex 
biologically relevant molecules like proteins, nucleic acids and enzymes [54]. It is now 
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possible to specifically detect microorganisms by functionalizing nanoparticles with 
specific antibodies and ligands. Since carbohydrate molecules are actively involved in 
host-cell recognition process leading to pathogenicity, coating the nanomaterials with 
such glycan molecules can provide a unique platform in rapid detection of pathogens 
including bacteria, virus and parasites. The underlying principle in this approach depends 
on the fact that providing multiple copies of different glycan molecules on the surface of 
nanomaterials would mimic the glycan present on the outer envelope of pathogen or the 
cell glycocalyx itself. Several studies have been carried out in this regard by exploiting 
the unique optical and magnetic properties of gold nanomaterials and magnetic 
nanomaterials respectively for rapid and specific detection of pathogens [55-65]. The 
adhesin-specific functionalized magnetic nanoparticles that we will be using in this 
research, can potentially find their application as unique nano-biosensor for rapid 
pathogen detection.  
Lin et al. were one of the first few groups who used mannose functionalized thiol-
coated gold nanoparticles as novel and sensitive agents for detecting E. coli cells in 
biological fluids proving the usefulness of carbohydrate functionalized nanoparticles in 
studying carbohydrate-protein adhesion [66]. They observed bacterial strain-specific 
aggregation of mannose functionalized gold nanoparticles via TEM imaging and UV-Vis 
spectroscopy. E. coli ORN 178 strain, which has FimH gene and type 1 pili showed 
specificity towards mannose functionalized gold nanoparticles whereas E. coli ORN 208 
strain, which lacked FimH gene and type 1 pili did not bind to nanoparticles.     
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Carbohydrate functionalized nanoparticles were also employed to rapidly detect bacterial 
toxins in biological solutions. Schofield and co-workers synthesized gold 
glyconanoparticles coated with lactose for colorimetric detection of cholera toxin (B 
subunit) [63]. They noticed a rapid change in the color of the gold nanoparticle solution 
when cholera toxin B was added to it and this was attributed to the shift in surface 
plasmon band of the nanoparticle solution, which takes place due to aggregation of these 
nanoparticles in presence of the toxin. Similarly, another study was undertaken by 
Kulkarni et al. in which they synthesized biocompatible glycan conjugated gold 
nanoparticles for selective inhibition of shiga toxin 1 and 2 in Vero monkey kidney cell-
line [64]. Their nanoparticles were functionalized with analogues of Pk trisaccharide 
molecules, which can mimic the glycolipid glycans present on the cell-surface receptors 
to which the toxin can attach. The results obtained by this work suggested a dose-
dependent inhibition of Stx toxin in Vero cells. 
 
Role of Carbohydrate Functionalized Nanomaterials in Anti-Adhesion 
Antimicrobial Therapy 
Advances in the fields of nanomaterials synthesis and synthetic glycoconjugate 
production have seen a rapid increase since early 2000. As new technologies are being 
developed, it has become relatively easy to custom synthesize different carbohydrate 
molecules/glycan conjugates and use them to bio-functionalize nanoparticles that can be 
then utilized in anti-adhesion therapies. Some of the most commonly employed 
nanomaterials in anti-adhesion therapies are gold nanoparticles, carbon nanotubes and 
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magnetic nanoparticles [67, 68]. To be effectively used as anti-adhesion agents, the 
carbohydrate molecules needs to have multivalent interactions with the host-cell surface 
receptors. For bacterial pathogens to initiate infection, they must be able to bind to host 
cell-surface receptors. These binding interactions are either carbohydrate-protein or 
carbohydrate-carbohydrate interactions in nature. Thus, in order to interrupt/inhibit these 
interactions, carbohydrate analog molecules that mimic the cell-surface receptors are 
frequently coated on the surface of nanoparticles thereby acting as novel anti-adhesion 
antimicrobial agents. Some of the early research studies carried out in these fields 
included gold and magnetic nanoparticles functionalized with mannose or galactose 
derivatives.  
For example, Huang et al. used silica-coated magnetic nanoparticles 
functionalized with mannose for rapid detection and separation of E. coli from medium 
[69]. After incubating mannose coated magnetic nanoparticles with bacterial cells, they 
applied external magnetic field to rapidly isolate the bacterial cells and their capture 
efficiency was ~88%. When these captured E. coli cells were observed under 
fluorescence microscopy and TEM imaging, they found large aggregates of 
nanoparticles-bacterial cells complex. These complex structures were attributed to lectin-
carbohydrate interactions taking place between adhesin molecules of E. coli and mannose 
molecules present on the surface of magnetic nanoparticles. Similar studies were carried 
out by Qu et al. wherein they functionalized the surface of polymeric nanoparticles with 
multiple copies of mannose/galactose and found out that E. coli 178 cells would 
agglutinate only in presence of mannose functionalized nanoparticles whereas E. coli 
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O157:H7 cells would aggregate only in the presence of galactose functionalized 
polymeric nanoparticles [60, 70]. Few other studies also showed anti-adhesion properties 
of carbohydrate-functionalized nanoparticles in mammalian cells as well as in turkey 
poults infected with Helicobacter pylori and Campylobacter jejuni respectively [68, 71]. 
 
Magnetic Nanoparticles 
Synthesis of magnetic nanoparticles: The synthetic approach to manufacture 
magnetic nanoparticles plays a very important role in determining the size, shape and its 
magnetic properties. Some of the main advantages of using superparamagnetic 
nanoparticles in the biological environment are increased surface area, improved 
diffusion rates in body fluids and tissues and high colloidal stability [72]. Commonly 
used approaches for synthesizing magnetic nanoparticles are co-precipitation, thermal 
decomposition, sol-gel synthesis, micro-emulsion, ligand-exchange reaction, 
hydrothermal and high-temperature reactions, polyol methods, spray pyrolysis, and 
aerosol/vapor methods [73]. Nonetheless, the common aim of all the above-mentioned 
synthesis methods is to achieve a highly stable and monodisperse nanoparticle suspension 
with suitable size requirements.  Moreover, it has been noticed that the size and shape of 
the nanoparticle is also dependent on the temperature, reaction time-period and 
concentration of the reagents. Keeping in view that these nanoparticles would interact 
with different biomolecules once they enter biological environment, it is imperative to 
make sure that the synthesized nanoparticles are highly nontoxic and in most of the cases, 
this depends on the method of nanoparticle synthesis [74]. Recently, nanoparticle 
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synthesis through high-temperature thermal decomposition technique has been 
efficaciously used in producing iron-oxide nanocrystals with enhanced controls in size 
distribution, shape and monodispersity with high degree of biocompatibility [75].  
Stabilization of magnetic nanoparticles with polymers: Uncoated magnetic 
nanoparticles tend to aggregate rapidly at neutral pH and in various biological 
environments. This aggregation takes place because of the strong dipole attractions in 
form of Van der Waals forces, occurring between the particles. To overcome this 
problem, stearic or electrostatic repulsion must be achieved which would then stabilize 
the nanoscale colloidal suspension. Addition of different polymers onto the core of 
magnetic nanoparticles would render high stability in biologically aqueous environments. 
The stabilizing agents can be briefly categorized into 3 classes’ namely 1) monomeric 
stabilizers which includes various functional groups like carboxylates, phosphates, and 
sulfates, 2) inorganic stabilizers which includes gold, silver, and silica, and 3) polymer 
stabilizers which are the most commonly used materials for stabilizing core magnetic 
nanoparticles [74].  
Some of the most commonly used polymer coatings for stabilizing core magnetic 
nanoparticle are dextran, starch, alginate, chitosan, polyethylene glycol (PEG) or 
polyethylene oxide (PEO), polyvinyl alcohol (PVA), polyethylene oxide (PEO), 
polyacrylic acid (PAA), and polyethylene amine (PEI) to name a few. Most of these 
polymers are reported to have good biocompatibility properties and thereby are 
extensively used in biomedical applications [76]. It has been also noticed that the 
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molecular weight and surface charge of these polymers play crucial role in determining 
the stability of nanoparticle suspension in biological environments [72, 74, 77, 78].  
PEG can be broadly classified into 2 categories depending on the type of terminal end 
group: 1) Monofunctional PEG - which has same functional group on both its ends and 2) 
Heterobifunctional PEG - which has 2 different reactive groups on each ends. Some of 
the most commonly used end terminal groups for PEGylation are acid chlorides, 
carbonates, aldehydes, amides, amine, carboxylic acids, NHS esters, etc. [78-81]. 
Some of the early studies involving usage of PEO for biomedical applications were 
carried out in 1970s. Abuchowski et al., for the first time, showed covalent attachment of 
PEG molecule (PEGylation) to bovine live enzyme, catalase [82]. They observed that 
attachment of PEG significantly increased the blood circulation time of these enzymes 
without triggering any immune response in mice. Since PEG is a known biocompatible 
polymer having no known cross-reaction with water molecules, it has been used 
extensively for drug delivery applications. Covalently attaching drug/protein molecules to 
PEG can increase its water solubility and overall hydrodynamic size. This actually helps 
in prolonged circulatory time as the increase in size diameter reduces its renal clearance 
rate. Some of advantages of attaching PEOs onto nanoparticles are that they are highly 
stable, biocompatible and approved by FDA, amphiphilic in nature, soluble in water as 
well as in many other solvents, can act as carrier molecule in different pharmaceutical 
products and the ease of manipulating its surface chemistry for wide-spread use in 




Generally, almost all materials are magnetic in nature to a certain level. When 
exposed to external magnetic field (H), they display varying amount of small magnetism. 
Accordingly, they can be classified as either 1) paramagnetic or 2) diamagnetic materials.  
Also, there are few materials that exhibit higher ordered magnetic states even in the 
absence of externally applied magnetic field. Such materials have been distinctly 
classified into 3 categories namely ferromagnetic, ferrimagnetic and antiferromagnetic 
materials. This classification has been based on the magnetic susceptibility of the 
magnetic materials.  
In paramagnetic materials, the magnetic moments are aligned parallel to H and 
they tend to retain their magnetic properties even when the external magnetic field is 
removed. In the case of diamagnetic materials, their magnetic properties are lost as soon 
as external field is removed. It should be noted that both para- and dia-magnetic materials 
have no collective magnetic interactions and their magnetic domains are not ordered. In 
ferri- and ferro-magnetic materials, the magnetic moments are also aligned parallel to H, 
however, there is a subtle difference in the coupling interactions that take place between 
the electrons of the magnetic material. The antiferromagnetic materials have the magnetic 
moments that are aligned anti-parallel to H. One of the unique features of all of the above 
3 materials is that they exhibit highly ordered state magnetic domains and large 
spontaneous magnetization [88].  
When the size of the nanoparticle goes below a certain value (~20 nm), then each 
individual nanoparticle can behave as a single magnetic domain that exhibits 
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superparamagnetic properties. When external magnetic field is applied, the magnetic 
dipoles to such nanoparticles will reorient and in the absence of magnetic field, the net 
magnetic moment will be zero. In contrast to paramagnetic materials, in 
superparamagnetic materials, the electrons spin alignment occurs in a single domain 
nanoparticle and not in a single atom. This is the reason as to why superparamagnetic 
nanoparticles respond very quickly in presence of external magnetic field [88]. When 
such nanoparticles are effectively stabilized with polymer coatings, they find myriad 
applications in the medical field.    
 
Use of Magnetic Nanoparticles in Magnetic Hyperthermia for 
Therapeutic Applications 
Hyperthermia is a type of treatment therapy wherein there is a drastic temperature 
increase in the body tissues. Hyperthermia therapy has been used for treating cancer since 
1957 [89]. Typically, heat treatment by means of hyperthermia can be classified into 3 
categories: mild temperature hyperthermia (37⁰C to 42⁰C), moderate hyperthermia (43⁰C 
to 46⁰C) and thermal ablation (>46⁰C). Moderate hyperthermia is clinically approved 
treatment option for cancer therapy. Some of the cellular processes, which are directly 
affected by hyperthermia, are protein degradation, heat stress, and induction of apoptosis 
in cancer cells [90]. In the last decade, several studies have established the potential of 
using nanomaterials in cancer therapy and disease management. Various biomolecules 
like DNA, RNA, peptides, mRNA, and antibodies have been used as targeting ligands to 
specifically deliver the nanomaterials to cancer cell/tissue. Among the different kinds of 
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nanomaterials used in cancer treatment, magnetic nanoparticles have been extensively 
studied because of their biocompatibility and multi-functionality. When magnetic 
nanoparticles are exposed to alternate magnetic fields, they generate heat and increase the 
temperature of the surrounding environment (conversion of magnetic energy into heat 
energy). This application is known as magnetic hyperthermia and it has been successfully 
employed in treating different kinds of cancers in vitro and in vivo [91]. This heat 
generation occurs because of Neel and Brown relaxation and hysteresis losses [92, 93] 
(Figure 1.2). The heat generation efficiency of MNPs in presence of AMF is measured in 
terms of specific absorption rate (SAR). The higher the SAR value, the better is the heat 
producing capacity of MNPs. It has been reported that SAR value is influenced by 
number of factors like nanoparticle size and its surface chemistry, its shape and applied 
frequency and field intensity of AMF [72]. Also, SAR value is dependent upon the 
exposure time of AMF and the solvent in which MNPs are suspended.  
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Figure 1.2 Schematic representation showing possible mechanisms of conversion of magnetic energy into heat energy. 
Reprinted from [89] - Reproduced with permission from Elsevier Ltd. and IEEE. 
 
Magnetic hyperthermia therapy using magnetic nanoparticles has been clinically 
used for treating tumors along with traditional chemotherapy and radiation therapy [94-
96]. Moreover, several studies have also attached a targeting molecule (e.g., antibody, 
protein molecule, anti-cancer drug) for cancer cells specific therapy using MNPs. In 
majority of these studies, due to presence of targeting molecule on the surface, the 
nanoparticles are able to attach and enter only in cancer specific cells. This has been 
found to be extremely advantageous as once the nanoparticles are attached to the cancer 
cells, applying alternate magnetic fields will heat up only the cancer specific cells/tissue 
leaving the non-cancer cells/tissue harmless [72, 90, 97-102] (Figure 1.3).  
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Figure 1.3 Magnetic nanomaterials based hyperthermia therapy applications. Reprinted from [89] - Reproduced with 
permission from Elsevier Ltd.  
 
Such targeted magnetic hyperthermia treatment can potentially revolutionize 
cancer therapy regimen by drastically reducing the side effects, which are usually found 
with chemotherapy. The heating rate of MNPs in magnetic hyperthermia is found to be 
dependent on numerous factors like concentration of nanoparticles, nanoparticle core size 
and shape of nanoparticles, surface chemistry of nanoparticles, applied frequency and 
field intensity of the instrument, and time [90]. Moreover, magnetic nanoparticles have 
also been successfully used as commercial contrasting agents in MRI imaging [91]. 
However, there are very few reports of treating bacterial infections by using magnetic 
hyperthermia [103-105].  
One such study performed by Thomas et al. used magnetic hyperthermia in 
presence of carboxylic-acid functionalized MNPs as alternative treatment option for 
killing Staphylococcus aureus cells [106]. They exposed the bacterial cells to AC 
magnetic field in presence of relatively high concentration of MNPs (up to 50 mg/ml). 
107-log reduction in bacterial counts was observed within 4 minutes of magnetic 
hyperthermia treatment in presence of 50 mg/ml concentration of MNPs. In another 
similar work, Park and co-workers studied the inactivation rate of Pseudomonas 
aeruginosa biofilms in presence of commercially available superparamagnetic iron oxide 
nanoparticles (SPIONs) and AC magnetic fields [104]. ~4-log reduction in biofilm was 
achieved through 8 minutes of magnetic hyperthermia treatment using concentration of 
60 mg/ml MNPs. They attributed this reduction to disintegration of bacterial cell 
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membrane at elevated temperatures, which are attained during the hyperthermia 
treatment. It should be duly noted that in both the above mentioned research studies, the 
killing of bacterial cells was mainly achieved by sheer increase in the bulk temperature 
through high concentrations of MNPs and AC magnetic fields. Also, none of the above 
studies utilized any specific targeting molecule/ligand for targeted hyperthermia therapy.  
 
Magnetically Mediated Energy Delivery (MagMED) 
 According to conventional theories, applying external alternate magnetic fields in 
presence of MNPs would result in macroscopic temperature rise and hence aptly referred 
to as magnetic hyperthermia therapy. The main drawback of this therapy is that to 
actually get a clinically relevant temperature increase in the living systems mainly in 
vitro and in vivo models, large concentrations of MNPs is needed. As majority of the on-
going clinical studies utilizing magnetic hyperthermia therapy through MNPs is for 
cancer treatment, it is not feasible to directly deliver such a large payload of nanoparticles 
to the desired location in the body via commonly administered routes, e.g., intravenous, 
intranasal, transdermal, intrathecal, etc. which could substantially increase the 
temperature of the body region/tissue.   
One possible way to reduce the concentration of MNPs to get desired results in 
terms of killing cancer cells or tumors is to actually make MNPs in such a way that they 
can be completely internalized by these cells and can target the intracellular pathways 
providing selective killing without actually rising the overall temperature of the system. 
In such cases, it would be incorrect to use the term magnetic hyperthermia. Hence, a few 
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research groups (Dr. Carlos Rinaldi, University of Florida; Dr. O. Thompson Mefford, 
Clemson University) coined the term ‘magnetically mediated energy delivery’ 
(MagMED) to explain the instances where apoptosis of cancer cells was achieved in 
presence of MNPs and alternate magnetic fields without a major change in the overall 
temperature of the system [100].  
Recent experimental studies have shed new insights on explaining how local 
temperature rise is attained during MagMED treatment without bulk temperature 
increases in tissue environment. A study by Huang et al. showed that it is possible to 
remotely activate calcium ion channels in neural cells through alternate magnetic fields 
with minimal changes in bulk temperature of the tissues [107]. They synthesized 
manganese ferrite nanoparticles functionalized with streptavidin, which can selectively 
bind to TRPV1 receptors in neural cells. Finally, they grafted thermal responsive 
fluorophores on the outer surface of nanoparticles and used alternate magnetic fields to 
thermally activate ion channels. Through this study, the authors were able to show ~20°C 
increase in local temperature on the surface of nanoparticles without bulk temperature 
rise based on the changes in the fluorescence intensity of the fluorophores that were 
present on the nanoparticles surface.  
In another study, Creixell and co-workers performed MagMED experiments in 
which they observed 99.9% reduction in viability of breast cancer cells in presence of 
iron-oxide nanoparticles [108]. They functionalized dextran-coated iron-oxide 
nanoparticles with epidermal growth factor (EGF) targeting ligands that can 
preferentially attach only to cancer cells. After MagMED therapy, they noticed that the 
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targeted nanoparticles were greatly internalized by the breast cancer cells compared to 
non-targeted ones and resulted in reduction in cell-viability of those cells. During this 
study, they did not notice any measurable increase in temperature when AMF was 
applied. An extension of the above study by the same research group tried to elucidate the 
underlying mechanism by which MNPs present in intracellular regions can prove toxic to 
cancer cells in presence of AMF without bulk temperature increase [109]. The same 
targeted group of nanoparticles were mixed with breast cancer cells and in presence of 
AMF, the internalized MNPs could selectively induce lysosomal membrane 
permeabilization of breast cancer cells. The authors suggested that increased lysosomal 
permeabilization could result in cellular death of breast cancer cells through increase in 
reactive oxygen species (ROS) and lysosomal cathepsins production in presence of AMF. 
In all of the above reported MagMED studies, the exact mechanisms of 
intracellular events that are responsible for apoptosis of cancer cells in presence of AMF 
and MNPs are still not fully understood. Some of the possible ways through which these 
events are currently explained are: 1) highly localized increase of temperature on the 
surface of nanoparticles can disrupt several signaling pathways in cells; 2) application of 
AMF in presence of MNPs can physically/mechanically damage the cell membrane via 






Biocompatibility of Magnetic Nanoparticles 
In last two decades, there has been tremendous increase in the usage of 
engineered nanomaterials for various industrial products and the demand is rapidly 
increasing. Analysts have forecasted that nanomaterial based industrial products will 
drive the global economic markets by more than 100 billion dollars per annum between 
the years 2011-2015 [110]. The flexibility to engineer different types of nanomaterials 
with desired physico-chemical properties has made it possible to use these nanomaterials 
in numerous biomedical applications. In fact, nanomaterials based treatment therapies for 
cancer diagnosis and therapy, drug delivery and imaging are already in clinical trial 
stages [111-117]. However, several factors regarding biocompatibility and toxicity of 
these nanomaterials still need to be addressed in detail. There is a complex relationship 
between the morphology, size and chemical properties of these nanomaterials that would 
eventually determine its toxicity in living organisms and the environment [110, 118-120]. 
The magnetic properties displayed by magnetic nanoparticles have been extensively 
utilized in wide range of biomedical applications like MRI imaging, drug delivery, 
pathogen detection, magnetic cell-separation or magnetic hyperthermia [80, 121-123]. 
Magnetic nanoparticles have also increased the overall efficacy of anticancer drugs and 
its presence has also reversed multidrug resistance commonly found in cancer cells [124]. 
To render magnetic nanoparticles biocompatible, they need to be coated with suitable 
polymers, which would keep them stable in biological environment. Depending on the 
overall size of the nanoparticle system, the stabilizing polymer and the type of chemical 
group present on the polymer end, MNPs can behave and interact differently with the 
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proteins present in the biological environment. Although magnetic nanoparticles have 
been reported to have excellent biocompatibility [125-127], they might exert toxicity to 
the host cell depending on their size, surface chemistry and its ability to interact with the 
proteins present in body fluids. Numerous in vitro and in vivo studies have demonstrated 
differential toxicity of MNPs [78, 79, 124, 128-131]. The different toxicity mechanisms 
observed in determining safe dosage levels of MNPs in these studies include impaired 
mitochondrial function, cytotoxicity, cell apoptosis, DNA damage and genotoxicity, 
immunotoxicity, oxidative stress, disordered cell morphology, cytoskeleton damage, cell-
membrane damage etc. [131-136]. Therefore, an in-depth and thorough analysis of 
toxicological profile of MNPs are warranted to make sure that they are biocompatible in 
living systems before using them clinical settings. 
 
Objectives 
MNPs bio-functionalized with different polymers and molecules have been 
researched widely for diverse biomedical applications. The kind of targeted moiety 
attached onto surface of MNPs determines the kind of interactions it would have with 
bacterial and mammalian cells. These interactions are greatly dependent on kind of 
synthesis procedures used for making MNPs, size of MNPs, type of polymer used as 
stabilizing agent and finally on the type of cell with which MNPs interacts both in in vitro 
and in vivo conditions. The main goal of this dissertation was to synthesize proof-of-
concept bacterial adhesin specific MNPs that are bio-functionalized with specific 
glycoconjugate molecule (GM3), and which can selectively interact with EC K99 strain 
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in absence/presence of AMF. The first aim deals with synthesizing mono-anchored GM3-
MNPs that are stabilized with heterobifunctional PEO polymer and evaluating its 
interactions with EC K99.  The second aim explores the feasibility of using multi-
anchored GM3-MNPs in conjunction with AMF for targeted killing of EC K99 both in 
pure and mixed culture environment and trying to explain the possible mechanisms 
through which EC K99 is destroyed. And the last aim investigates the biocompatibility 
and interaction of our novel MNPs system with normal human colon cells CCD-18Co by 
employing various toxicity assays. The results obtained in this project will greatly help in 
providing a unique non-antibiotic platform for treating bacterial infections via MNPs and 
AMF with minimum toxicity to host-tissue. 
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Synthesis and Application of Glycoconjugate-Functionalized Magnetic 
Nanoparticles as Potent Anti-adhesion Agents for Reducing 
Enterotoxigenic Escherichia coli Infections 
[This chapter is taken directly or adapted from work published in Nanoscale journal by 
Raval et al. (2015); DOI: 10.1039/c5nr00511f. Copyrights 2015 - Reproduced by 




There has been a recent uprising in the emergence of new multi-drug resistant 
bacterial strains in the environment, which has resulted in increased morbidity and 
mortality throughout the world [1-3]. As a result, alternative therapeutic options that are 
non-antibiotic based are urgently needed to treat such bacterial infections. There have 
been considerable ongoing scientific interests in understanding multivalent carbohydrate-
lectin interactions for various purposes like receptor mimicking, inhibiting bacterial 
growth and as novel anti-adhesion agents for treating bacterial infections [4-8]. 
Functionalizing multivalent carbohydrate molecules onto the surface of different 
nanomaterials offers numerous advantages, e.g., higher affinity constants (Ka) and 
enthalpy of binding (ΔH) [9, 10], than their monovalent forms in studying ligand-receptor 
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interactions [11]. Nonetheless, there have been limited reports of using such 
carbohydrate-functionalized nanomaterials as specific anti-bacterial and anti-adhesion 
agents. Due to high surface/volume ratio of nanoparticles, it is relatively easy to attach 
various carbohydrate moieties onto their surface, which has found useful applications in 
rapid pathogen/toxin detection and its inhibition [12-14]. In several studies, gold 
nanoparticles [15], magnetic nanoparticles [16], carbon nanotubes [17, 18], polymeric 
nanoparticles [19-21], and diamond nanoparticles [22] were bio-functionalized with 
various carbohydrate sugars and used as mimicking agents of host-cell surface receptors 
that selectively interacted with the adhesin molecules of various E. coli strains and 
resulted in rapid agglutination [20] and reduction in colony forming units (CFUs) of these 
E. coli strains [21]. The unique magnetic properties and biocompatibility displayed by 
magnetic nanoparticles have been extensively utilized in wide range of biomedical 
applications like MRI imaging [23], pathogen detection [24], drug-delivery [25], and 
magnetic hyperthermia [26]. Keeping MNPs stable in biological environments is 
important in their biomedical applications. Numerous polymer anchor groups like amines 
[27], alcohols [28], phosphates [29], and carboxylic acids [30] have been utilized to 
render colloidal stability to MNPs in highly protein-rich biological environments. Of late, 
anchor groups based on catechols have been extensively researched to provide stable 
platform for synthesizing multifunctional MNPs [31-34]. 
Bacterial pathogens utilize two primary mechanisms to adhere onto the host-cell 
namely carbohydrate-protein recognition and protein-protein interaction [35]. Bacterial 
adhesin molecules, which take part in carbohydrate-protein interaction, bind bacterial 
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pathogens onto the host-cell tissue through specific glycolipid or glycoprotein receptors 
[36]. Enterotoxigenic Escherichia coli (ETEC) infection is one of the most common 
cause of traveler’s diarrhea in humans and also in neonatal farm animals like calves, pigs 
and lambs [37]. Recently, numerous studies have reported increases in multi-drug 
resistance of ETEC associated with antibiotic treated animal feed [38-41]. Majority of the 
fimbrial adhesins isolated from ETEC that infected farm animals expressed one or more 
unique adhesins. These adhesins also act as antigens/virulence factors [41]. EC K99 is the 
main causative agent of bloody diarrhea in young calves, lambs and pigs, a condition also 
known as colibacillosis. This strain bears K99 antigens, which also act as fimbriae 
facilitating the adherence of EC K99 onto the ileal villus epithelium of calf and pigs and 
help in initiation of infection [42, 43]. The adhesins of EC K99 specifically attach to 
small intestinal mucus and recognize sialic acid derivatives present on glycolipid 
receptors [4, 44]. Hence, if this attachment is disrupted, then there is high probability of 
preventing bacterial infection. 
The use of bacterial adhesin-specific glycoconjugate functionalized nanoparticles 
for prevention/treatment of infections offers several advantages in that it can be designed 
to target only a specific strain or a specific group of pathogens; it does not impose 
selection pressure on bacteria exposed to it, hence, minimizing the emergence of resistant 
bacteria; it is more stable and less expensive than antibodies-based targeting systems, etc. 
In our previous lab research, we have demonstrated that gold nanoparticles bio-
functionalized with specific sialic-acid sequences can cause rapid aggregation of EC K99 
[45]. Here, we extend our work and further study the intricate details of glycoconjugate 
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receptor binding specificity of this sequence molecule (Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp) 
coated on MNPs (GM3-MNPs) towards EC K99 by employing various microscopic 
techniques and bioassays and show that these MNPs can effectively act as novel non-
toxic anti-adhesion agents in reducing ETEC infections. 
 
2. Experimental Section: 
Synthesis of Heterobifunctional Polyethylene Oxide (alkyne-PEO-nitroDOPA): 
The chemical synthesis of heterobifunctional polyethylene oxide polymer having alkyne 
at one end and nitroDOPA on the other end is schematically shown in figure 2.1. This 
complex polymer was synthesized by Roland Stone (PhD student in Dr. O. Thompson 
Mefford’s group, Clemson University). More details regarding the intricate experimental 
steps involved in synthesizing this polymer and its characterization can be found in the 
publication, Stone et al. 2014 [46]. 
Synthesis of Magnetic Nanoparticles: The 7.2nm magnetic nanoparticles, 
synthesized using thermal decomposition of iron(III) acetylacetonate (2mmol), 1,2-
hexadecanediol (10mmol), olylamine (4mmol), benzyl ether (20ml), and 6nm iron oxide 
seeds were added and stirred under a nitrogen flow and brought to 200°C for 1hr to get 
rid of any moisture. Finally the reaction was brought to reflux for 30mins under a 
nitrogen head. The particles were purified by precipitation of ethanol and characterized 
using TEM and DLS.  
Modification of Magnetic Nanoparticles: The magnetic nanoparticles were 
modified by first dissolving alkyne-PEO-nitroDOPA (200 mg, 0.04mmol) into 10ml of 
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chloroform followed by the slow addition of 1ml (2mg/ml) of magnetic nanoparticles, 
which were also dispersed in chloroform, while sonicating over 30 mins. The solution 
was allowed to stir overnight. The particles were then purified by precipitation with 
hexane, centrifuged to separate particles from solvent. They were then dispersed in 
ethanol and subsequently precipitated using hexane and separated via centrifugation to 
collect particles. Finally, the particles were dispersed in deionized water and dialyzed for 
3 days. 
Synthesis of Magnetic Nanoparticles Functionalized with GM3 
Glycoconjugate: The particles with an alkyne surface were then modified using ‘click 
chemistry’ with glycoconjugate (Neu5Ac(α2-3)-Gal(β1-4)Glcβ-sp) and azide, 1 : 4 
respectively using a copper catalyst for 24 hours in the absence of light. The particles 
were then dialyzed for 3 days to remove any unbound glycoconjugate, catalyst, and any 
byproducts of the reaction. 
Dynamic Light Scattering (DLS) and Zeta-Potential: DLS was performed on the 
PEO-coated and GM3-coated magnetic nanoparticles to determine their hydrodynamic 
radius. The nanoparticle suspensions were diluted in water and placed into a cuvette. 
Three readings were taken at 25°C using Malvern Zetasizer Nano ZS to determine the 
intensity average size distribution and z-average diameter. Zeta-potential measurements 
of these nanoparticle suspensions were also determined using the same instrument. The 
suspensions were diluted with water and added into zeta-cell and three measurements 
were taken at 25°C. 
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Inductively Coupled Plasma Mass Spectroscopy (ICP-MS): The nanoparticle 
concentration in PEO-MNPs and GM3-MNPs was determined by performing ICP-MS 
(Thermo-Scientific MS XSeries 2). The nanoparticle suspensions were treated with 2% 
nitric acid solution in a 15 ml centrifuge tube and subsequently measurements were 
taken.    
 Fourier Transform Infrared Spectroscopy (FTIR): FTIR assisted 
microscopy was done using a Thermo-Nicolet Magna 550 FTIR spectrometer equipped 
with a Thermo-NicPlan FTIR microscope. Scan number was 16 for each sample 
including background. Background was collected on a clean germanium plate. Samples 
were prepped by taking the water suspensions/solution and casting a small drop on a 
germanium plate. The samples were then set under a heat lamp for 10-15 minutes to dry, 
resulting in a thin film from which spectrum could be collected using an FTIR 
microscope.  
 Fluorescence Microscopy Aggregation Assay: Both EC K99 (ATCC 13762) 
and non-virulent strain E. coli O157:H7 6980-2 (EC 6980-2; control strain) were 
transformed with plasmids pGREEN and pGFPuv respectively by 
electroporation[47]. The green-fluorescent protein (GFP) expressing E. coli strains 
were grown in tryptic soy broth/tryptic soy agar (TSB/TSA) supplemented with 
ampicillin (100 µg/ml).  Freshly grown E. coli cultures were used for aggregation 
assays. After growth, the bacterial cells were centrifuged thrice and re-suspended 
in 1X sterile phosphate buffered saline (PBS). Approximately, 5 x 107 CFU of 
bacterial cells were prepared based on optical density (OD600) readings. PEO-
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MNPs (40 µg/ml) and GM3-MNPs (40 µg/ml) were mixed with both EC K99 and 
EC 6980-2 and this mixture was incubated at room temperature for 30 minutes 
with gentle shaking. Based on previous method [21], fluorescence microscopy 
assays were performed at the end of incubation time to visualize nanoparticles-
mediated bacterial aggregation. 
TEM Imaging of GM3-MNPs and EC K99: TEM imaging was performed to 
evaluate the specific binding interactions between GM3-MNPs and EC K99. GM3-MNPs 
were added to EC K99 (5 x 107 CFU/ml, suspended in 1X PBS) in an eppendorf tube for 
30 minutes at room temperature with gentle shaking. The mixture was centrifuged at 
7000 x g for 5 minutes to spin down the bacterial cells along with adherent GM3-MNPs. 
The supernatant containing unbound GM3-MNPs was removed and the pellet was 
washed thrice with 1X PBS in repeated centrifugation cycles. This mixture was then 
fixed in cacodylate-buffered glutaraldehyde (3.5%, pH ~7.4) for 10 -12 hours at 4°C. 
Subsequently, 3 µl of this mixture was dropped onto a carbon-coated copper grid and 
allowed to air-dry for 30 minutes. Later, the grids were stained with 2% uranyl acetate 
solution (3 µl) for 5 minutes and blotted dry with filter-paper (Whatman #4). TEM 
images were taken on Hitachi H7600 at 120 kV power and magnification ranging from 
10000X to 100000X.  
 CFU Aggregation Assay: In order to determine the extent of GM3-MNPs 
induced bacterial aggregation, a CFU reduction assay was carried out as previously 
described [21]. Briefly, both the E. coli strains were standardized to a 
concentration of 5 x 107 CFU in 1X PBS. These bacterial suspensions were then 
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mixed with different amounts of PEO-MNPs and GM3-MNPs (40 µg/ml and 100 
µg/ml) and the mixture was allowed to incubate at room temperature for 30 
minutes with gentle shaking. Serial dilutions of these mixtures were made and 50 
µl of sample from each dilution tube was transferred onto a sterile, empty petri 
plate in triplicates. Then, 20 ml of molten TSA (maintained at 45°C) supplemented 
with ampicillin (100 µg/ml) was carefully poured into the petri plates. The plates 
were gently rotated to ensure proper mixing of sample and TSA. Finally, after the 
TSA in the plates solidified, the plates were incubated at 37°C overnight. Next 
day, the colonies on the plates were counted and CFU reduction was compared to 
control plates.  
ATP Assay: To confirm that the reduction in CFU of EC K99 was achieved only 
due to GM3-MNPs induced bacterial aggregation and not because of inherent toxicity of 
these nanoparticles, an ATP determination assay [48] was performed using BacTiter-
Glo™ microbial cell viability kit (Promega, Madison, WI) following manufacturer’s 
protocol. 
Cytotoxicity Assay: To further validate the non-toxic nature of our nanoparticles 
system, we performed a preliminary cytotoxicity assay on human colon (normal) cell-line 
CCD-18Co and determined its cell-viability rate after exposing to GM3-MNPs for 24 
hours. CCD-18Co Human colon cells (normal) were procured from American Type 
Culture Collection (ATCC) and grown on 50 cm2 tissue-culture flask (Corning, NY) in 
the presence of Eagle’s Minimum Essential Medium (EMEM) at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air. EMEM was supplemented with 2 mM L-Glutamine, 
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non-essential amino acids, fetal bovine serum (final concentration – 10%), 100 UI/ml 
penicillin G, and 100 µg/ml streptomycin. For determining the cytotoxicity of GM3-
MNPs, cells between passage generation of 12 and 20 were used. 1.5 x 104 cells/well 
were seeded (in triplicates) in 96-well culture-plates at 37°C in a humidified atmosphere 
of 5% CO2 and 95% air. After 24 hours, varying concentration of GM3-MNPs were 
added to the cells and incubated for further 24 hours. Next day, MTS assay (CellTiter 96® 
Aqueous One Solution Cell Proliferation Assay, Promega, USA) was performed 
according to manufacturer’s protocol and the plate was read at 490 nm optical density to 
measure the absorbance of the formazan product using a microplate reader (Thermo 
Scientific Multiskan™ FC). 
 
3. Results and Discussion: 
In this chapter, we report the synthesis of MNPs coated with heterobifunctional 
polyethylene oxide (PEO-MNPs) having nitroDOPA as a stable anchoring agent and bio-
functionalized with sialic-acid glycoconjugate (Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp) (GM3-
MNPs) via ‘click chemistry’(Figure 2.1). These GM3-MNPs can effectively act as 
multivalent ligands, which specifically interact with adhesins present on the EC K99.  
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Figure 2.1 Synthesis of heterobifunctional polyethylene oxide coated magnetic nanoparticles bio-functionalized with 
sialic-acid derivative (Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp). 
A heterobifunctional polyethylene oxide (PEO), with a molecular weight of 6300 
g/mol, with a protected alcohol on one end and an alcohol on the other was synthesized 
by the anionic polymerization of ethylene oxide (EO) using tetrahydropyranol as an 
initiator. The alcohol end group was then modified with an alkyne via a substitution 
reaction using propargyl bromide (1:4 respectively). Once modified, the protected alcohol 
group was deprotected with an acid and subsequently purified. Finally, using N-
hydroxysuccinimide (NHS) and N,N'-dicyclohexylcarbodiimide (DCC) coupling, the 
heterobifunctional PEO was modified with nitrated 3,4 dihydroxy-L-phenylanaline 
(nitroDOPA) to yield a macromolecule with functionality that can be utilized for ‘click 
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previous work by Stone et al.[46], where synthetic details the polymer formation and 
relevant NMR data can be found. NitroDOPA was selected as the binding group for our 
system because of its enhanced binding to metal oxides [49]. 
The aforementioned macromolecule was then used to modify MNPs, synthesized 
using a modified version of a procedure by Sun et al.,[50]  via ligand-exchange by slowly 
adding magnetic nanoparticles dispersed in hexanes to a solution of the macromolecule in 
chloroform while sonicating. After 12 hours, allowing for significant ligand exchange, 
the polymer-particle complex was then purified by extraction into DI water and then 
dialyzed against DI water in 12-14,000 g mol-1 MWCO dialysis membranes for three 
days to remove any impurities. The use of nitroDOPA containing PEO polymer has 
recently been shown to be the most effective anchoring chemistry in the ligand exchange 
of oleic acid coated particles [51]. The resulted particles with attached glycoconjugate 
(GM3-MNPs) were characterized by dynamic light scattering (DLS) (Table 2.1), zeta-
potential (Table 2.1) and FT-IR spectroscopy (Figure 2.2 and 2.3). The absence of azide 
peak at 2113 cm-1 in Figure 2.2 (D) represents the successful conjugation of 
glycoconjugate moiety onto the polymer-coated magnetic nanoparticles through 
cycloaddition. The nanoparticle concentration in PEO-MNPs and GM3-MNPs was 
determined by means of inductively coupled plasma mass spectroscopy (ICP-MS).  
Type of MNPs DLS (Z – Avg) (d. nm) Zeta-Potential 
PEO-MNPs 77.31 -12.1 
GM3-MNPs 80.46 -42.0 
 
Table 2.1 DLS and Zeta-Potential measurements of MNPs after functionalizing PEO polymer and GM3 molecule. 
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Figure 2.2 FTIR of DOPA (Top) and NitroDOPA (Bottom). Symmetric and asymmetric stretching from the NO2 peaks 
at 1330 and 1532 cm-1. Reprinted from (46) - Reproduced by permission of The Royal Society of Chemistry. 
 
Figure 2.3 FTIR spectroscopy of A.) Magnetite particles modified with the alkyne PEO stabilizer, B.) The Neu5Ac(α2-
3)Gal(β1-4)Glcβ-sp targeting moiety prior to “clicking”, C.) The resulting complex of magnetic nanoparticles with the 
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Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp moiety, and D.) The resulting spectrum of subtracting spectrum C by A indicating the 
successful conjugation of the Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp to targeting molecule. 
 
Clearly, large aggregates of EC K99 were observed in the presence of GM3-
MNPs (Figure 2.4). No visible aggregation was found when EC K99 was mixed with 
PEO-MNPs (Figure 2.4 c). Moreover, EC 6980-2 did not form aggregates when mixed 
with PEO-MNPs and GM3-MNPs (Figures 2.4 a and b). This shows that both E. coli 
strains clearly have different sugar binding specificities and that EC K99 exhibits binding 
specificity only to GM3-MNPs.  
 
Figure 2.4 Fluorescent microscopy images of EC 6980-2 and EC K99 in presence of PEO-MNPs and GM3-
MNPs. (a) and (b) EC 6980-2, in the presence of PEO-MNPs and GM3-MNPs respectively; (c) and (d) EC 
K99, in the presence of PEO-MNPs and GM3-MNPs respectively. Magnification – 400X and scale bar – 100 
µm. 
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Furthermore, transmission electron microscopy (TEM) analysis of the mixture 
containing GM3-MNPs and EC K99 was done to observe intricate details of bacterial 
aggregation. The samples for TEM analysis were prepared according to a modified multi-
step protocol [21, 52]. Large clusters of bacterial cells were observed due to strong 
interactions between GM3-MNPs and EC K99 (Figure 2.5 a and b). The GM3-MNPs 
were found covering the entire surface of EC K99. Because of significant binding of 
multiple GM3-MNPs onto individual bacterial cells and other GM3-MNPs acting as 
linking agents to interact with other bacterial cells, we observed significantly large 
agglutination of EC K99.  
 
Figure 2.5 TEM images of GM3-MNPs induced bacterial aggregation of EC K99. Magnification of (a) and (b) are 
30000X and 60000X, respectively. Scale bar is 500 nm. 
Entero-pathogenic E. coli strains have different sugar binding affinities depending 
on the type of adhesins present on their outer cell-surface [53]. It is known that EC K99 
has S type of fimbrial proteins that specifically recognizes and binds only to Neu5Ac(α2-
3)Gal(β1-4)Glcβ-sp sialic-acid sequences [4]. The pilus of EC K99 is primarily made up 
of FanC, major fimbrial sub-unit gene product, which is responsible for recognizing and 
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attaching the bacterium to the sialic-acid ganglioside receptors present on the host-cell 
[54]. On the other hand, EC 6980-2 have adhesin molecules that consist of galactose-
binding proteins on its outer surface which can attach to galactose receptors [17] present 
on the host-cell and hence EC 6980-2 was not able to form bacterial aggregates when 
mixed with GM3-MNPs. Based on these sugar-binding specificities, the above mentioned 
2 different E. coli strains were selected for this study.  
 As shown in figure 2.6 A, approximately 2-log reduction in CFU of EC K99 
was observed in the presence of GM3-MNPs (40 µg/ml). This reduction was due to 
GM3-MNPs induced bacterial aggregation. Also, 1-log reduction of EC K99 was 
observed at 100 µg/ml concentration of GM3-MNPs. Interestingly, there was no 
reduction in CFU of EC 6980-2 in the presence of either GM3-MNPs or PEO-MNPs 
(Figure 2.6 B). These results correlate with those obtained in fluorescence microscopy 
assay showing that bacterial cells of EC K99 aggregating in clusters of several 100s of 
bacterial cells in the presence of GM3-MNPs. Surprisingly, EC K99 in the presence of 
GM3-MNPs (100 µg/ml) resulted only in 1-log reduction in CFU since the nanoparticle-
bacteria ratio was different. Luo and co-workers [21] obtained similar results when they 
incubated E. coli ORN178 in the presence of different concentrations of mannose-
functionalized polymeric nanoparticles. Thus, it is imperative to attain appropriate 
nanoparticle-bacteria ratio for getting maximum reduction in CFU mediated by 
nanoparticles-induced bacterial aggregation. 
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Figure 2.6 (a) CFU/ml assay of EC K99 in the presence of different concentrations of GM3-MNPs and PEO-MNPs 
and (b) CFU/ml assay of EC 6980-2 in the presence of different concentrations of GM3-MNPs and PEO-MNPs. Data 
expressed as Mean ± SD (n = 3); Statistical Analysis – Two-Way Analysis of Variance (ANOVA) (*** - P<0.0001). 
 
 Intracellular ATP levels of both the E. coli strains were recorded by 
measuring their relative luminescence in the presence/absence of GM3-MNPs (40 µg/ml) 
and PEO-MNPs (40 µg/ml). Figures 2.7 A and B shows that there is no significant 
difference in intracellular ATP levels of both E. coli strains in the presence of 
nanoparticles. Also, another important feature to determine the toxicity of nanoparticles 
is to look for any cell-membrane damage and morphological changes in the bacterial cell-
membrane structure [52]. Results of TEM imaging of EC K99 in the presence of GM3-
MNPs showed no visible bacterial cell-membrane damage suggesting the non-toxic 
nature of our nanoparticles. These results suggest that the reduction in CFU of EC K99 
was achieved only because of GM3-MNPs induced bacterial aggregation and not due to 
nanoparticle toxicity.  
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Figure 2.7 Intracellular ATP Assay (a) Relative Luminescent Units (RLU) of EC K99 when incubated with GM3-
MNPs and PEO-MNPs (b) RLU of EC 6980-2 when incubated with GM3-MNPs and PEO-MNPs. Data expressed as 
Mean ± SD (n = 3); Statistical Analysis – One-Way Analysis of Variance (ANOVA); (P>0.05). 
 
To further validate the non-toxic nature of our nanoparticles system, we 
performed a preliminary cytotoxicity assay on human colon (normal) cell-line CCD-18Co 
and determined its cell-viability rate after exposing to GM3-MNPs for 24 hours. The 
potential cytotoxicity of GM3-MNPs was measured by performing MTS assay. As seen 
in figure 2.8, there was no significant reduction in cell-viability rate of CCD-18Co cells 
in the presence of varying concentrations of GM3-MNPs. These results suggest that our 




Figure 2.8 Cytotoxicity assay to determine cell-viability of CCD-18Co cells in presence of different concentrations of 




In conclusion, we successfully synthesized heterobifunctional polymer coated 
magnetic nanoparticles that have nitroDOPA as a stable anchoring agent and were bio-
functionalized with sialic-acid glycoconjugate (Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp) (GM3-
MNPs) using click chemistry. The GM3-MNPs were characterized by employing 
different techniques and their adhesin specificity was determined using aggregation 
assays. Our GM3-MNPs specifically interacted only with ETEC strain EC K99 as 
confirmed through fluorescence microscopy and transmission electron microscopy. Also, 
a 2-log reduction in CFU of EC K99 was achieved due to GM3-MNPs induced bacterial 
aggregation. Moreover, intracellular ATP assays demonstrated that the 2-log reduction in 
CFU of EC K99 was not due to inherent toxicity of the nanoparticles. Thus, our proof-of-
concept nanoparticle system can effectively serve as novel non-antibiotic multivalent 
carriers, which could find applications in detection and capturing of pathogenic multi-
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drug resistant bacterial strains from active physiological body fluids. Our systems can 
especially reduce/treat gastro-intestinal tract infections caused by ETEC pathogens in 
farm animals and humans since specific bacterial-nanoparticle aggregates can be 
effectively flushed out from the body system because of high peristaltic flows without 
disturbing the normal gut microflora that is usually destroyed when antibiotics are used. 
This system can also be employed as potent anti-adhesion agents that can block/inhibit 
specific cellular responses by competitively preventing the attachment of bacterial 
pathogens onto specific eukaryotic cell-surface receptors and thereby reducing the 
infection load. Furthermore, this nanoparticle system can also be utilized for targeted 
magnetic hyperthermia treatment of bacterial infections, especially those that are resistant 
to multiple antibiotics. In future work, nanoparticles with multi-anchored functional 
groups will be utilized to improve stability of nanoparticles in biological fluids and to 
enhance their bindings to specific pathogens. Their therapeutic values, i.e., selective 
killing of pathogens via hyperthermia mediated by glycoconjugate-functionalized 
magnetic nanoparticles, will be evaluated both in vitro in cell-line and in vivo in small 
animal systems. In addition, potential toxicities associated with the use of these 
nanoparticles will be characterized using various biological assays, e.g., cytotoxicity, 
genotoxicity, immunogenicity assays, etc. 
 
References: 
1. Walsh, C., Antibiotics: actions, origins, resistance. 2003: American Society for 
Microbiology (ASM). 
2. Levy, S.B. and B. Marshall, Antibacterial resistance worldwide: causes, 
challenges and responses. Nature Medicine, 2004. 10: p. S122-S129. 
 54 
3. Jones, K.E., et al., Global trends in emerging infectious diseases. Nature, 2008. 
451(7181): p. 990-993. 
4. Sharon, N., Carbohydrates as future anti-adhesion drugs for infectious diseases. 
Biochimica et Biophysica Acta, 2006. 1760(4): p. 527-537. 
5. Ernst, B. and J.L. Magnani, From carbohydrate leads to glycomimetic drugs. 
Nature Reviews Drug Discovery, 2009. 8(8): p. 661-677. 
6. Tra, V.N. and D.H. Dube, Glycans in pathogenic bacteria–potential for targeted 
covalent therapeutics and imaging agents. Chemical Communications, 2014. 
50(36): p. 4659-4673. 
7. Zopf, D. and S. Roth, Oligosaccharide anti-infective agents. Lancet, 1996. 
347(9007): p. 1017-1021. 
8. Karlsson, K.A., Meaning and therapeutic potential of microbial recognition of 
host glycoconjugates. Molecular Microbiology, 1998. 29(1): p. 1-11. 
9. Dam, T.K., et al., Binding of Multivalent Carbohydrates to Concanavalin A and 
Dioclea grandiflora Lectin THERMODYNAMIC ANALYSIS OF THE 
“MULTIVALENCY EFFECT”. Journal of Biological Chemistry, 2000. 275(19): 
p. 14223-14230. 
10. Luque, I. and E. Freire, Structural parameterization of the binding enthalpy of 
small ligands. Proteins: Structure, Function, and Bioinformatics, 2002. 49(2): p. 
181-190. 
11. Marradi, M., I. Garcia, and S. Penades, Carbohydrate-based nanoparticles for 
potential applications in medicine. Progress in Molecular Biology and 
Translational Science, 2011. 104: p. 141-173. 
12. Marradi, M., et al., Glyconanoparticles as multifunctional and multimodal 
carbohydrate systems. Chemical Society Reviews, 2013. 42(11): p. 4728-4745. 
13. Marradi, M., M. Martin-Lomas, and S. Penades, Glyconanoparticles polyvalent 
tools to study carbohydrate-based interactions. Advances in Carbohydrate 
Chemistry and Biochemistry, 2010. 64: p. 211-290. 
14. Bernardi, A., et al., Multivalent glycoconjugates as anti-pathogenic agents. 
Chemical Society Reviews, 2013. 42(11): p. 4709-4727. 
15. Lin, C.-C., et al., Selective binding of mannose-encapsulated gold nanoparticles 
to type 1 pili in Escherichia coli. Journal of the American Chemical Society, 
2002. 124(14): p. 3508-3509. 
16. El-Boubbou, K., C. Gruden, and X. Huang, Magnetic glyco-nanoparticles: a 
unique tool for rapid pathogen detection, decontamination, and strain 
differentiation. Journal of the American Chemical Society, 2007. 129(44): p. 
13392-13393. 
17. Gu, L., et al., Single-walled carbon nanotubes displaying multivalent ligands for 
capturing pathogens. Chemical Communications, 2005(7): p. 874-876. 
18. Gu, L., et al., Single-walled carbon nanotube as a unique scaffold for the 
multivalent display of sugars. Biomacromolecules, 2008. 9(9): p. 2408-2418. 
19. Qu, L.W., et al., Galactosylated Polymeric Nanoparticles: Synthesis and 
Adhesion Interactions with Escherichia coli. Journal of Biomedical 
Nanotechnology, 2005. 1(1): p. 61-67. 
 55 
20. Qu, L., et al., Visualizing adhesion-induced agglutination of Escherichia coli with 
mannosylated nanoparticles. Journal of Nanoscience and Nanotechnology, 2005. 
5(2): p. 319-322. 
21. Luo, P.J.G., et al., Quantitative Analysis of Bacterial Aggregation Mediated by 
Bioactive Nanoparticles. Journal of Biomedical Nanotechnology, 2005. 1(3): p. 
291-296. 
22. Barras, A., et al., Glycan-functionalized diamond nanoparticles as potent E. coli 
anti-adhesives. Nanoscale, 2013. 5(6): p. 2307-2316. 
23. Dave, S.R. and X. Gao, Monodisperse magnetic nanoparticles for biodetection, 
imaging, and drug delivery: a versatile and evolving technology. Wiley 
Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009. 1(6): p. 
583-609. 
24. Kaittanis, C., S. Santra, and J.M. Perez, Emerging nanotechnology-based 
strategies for the identification of microbial pathogenesis. Advanced Drug 
Delivery Reviews, 2010. 62(4-5): p. 408-423. 
25. Arruebo, M., et al., Magnetic nanoparticles for drug delivery. Nano Today, 2007. 
2(3): p. 22-32. 
26. Kumar, C.S. and F. Mohammad, Magnetic nanomaterials for hyperthermia-based 
therapy and controlled drug delivery. Advanced Drug Delivery Reviews, 2011. 
63(9): p. 789-808. 
27. Aslam, M., et al., Synthesis of amine-stabilized aqueous colloidal iron oxide 
nanoparticles. Crystal Growth & Design, 2007. 7(3): p. 471-475. 
28. Lin, H., et al., Preparation of magnetic poly (vinyl alcohol)(PVA) materials by in 
situ synthesis of magnetite in a PVA matrix. Journal of Applied Polymer Science, 
2003. 87(8): p. 1239-1247. 
29. Sahoo, Y., et al., Alkyl phosphonate/phosphate coating on magnetite 
nanoparticles: a comparison with fatty acids. Langmuir, 2001. 17(25): p. 7907-
7911. 
30. Vadala, M., et al., Heterobifunctional poly (ethylene oxide) oligomers containing 
carboxylic acids. Biomacromolecules, 2008. 9(3): p. 1035-1043. 
31. Gu, H., et al., Synthesis and cellular uptake of porphyrin decorated iron oxide 
nanoparticles—a potential candidate for bimodal anticancer therapy. Chemical 
Communications, 2005(34): p. 4270-4272. 
32. Amstad, E., et al., Surface functionalization of single superparamagnetic iron 
oxide nanoparticles for targeted magnetic resonance imaging. Small, 2009. 5(11): 
p. 1334-1342. 
33. Saville, S.L., et al., Investigation of the stability of magnetite nanoparticles 
functionalized with catechol based ligands in biological media. Journal of 
Materials Chemistry, 2012. 22(47): p. 24909-24917. 
34. Amstad, E., et al., Ultrastable iron oxide nanoparticle colloidal suspensions using 
dispersants with catechol-derived anchor groups. Nano Letters, 2009. 9(12): p. 
4042-4048. 
35. Ofek, I. and R.J. Doyle, Bacterial adhesion to cells and tissues. 1994: Chapman 
& Hall New York. 
 56 
36. Sharon, N., Bacterial lectins, cell-cell recognition and infectious disease. FEBS 
Letters, 1987. 217(2): p. 145-157. 
37. Black, R.E., Epidemiology of travelers' diarrhea and relative importance of 
various pathogens. Reviews of Infectious Diseases, 1990. 12 Suppl 1: p. S73-9. 
38. Barigye, R., et al., Prevalence and antimicrobial susceptibility of virulent and 
avirulent multidrug-resistant Escherichia coli isolated from diarrheic neonatal 
calves. American Journal of Veterinary Research, 2012. 73(12): p. 1944-1950. 
39. de Verdier, K., et al., Antimicrobial resistance and virulence factors in 
Escherichia coli from Swedish dairy calves. Acta Veterinaria Scandinavica, 2012. 
54(1): p. 2-2. 
40. Güler, L., K. Gündüz, and Ü. Ok, Virulence factors and antimicrobial 
susceptibility of Escherichia coli isolated from calves in Turkey. Zoonoses Public 
Health, 2008. 55(5): p. 249-257. 
41. Nagy, B. and P.Z. Fekete, Enterotoxigenic Escherichia coli (ETEC) in farm 
animals. Veterinary Research, 1999. 30(2-3): p. 259-284. 
42. Nagy, B., H.W. Moon, and R.E. Isaacson, Colonization of porcine intestine by 
enterotoxigenic Escherichia coli: selection of piliated forms in vivo, adhesion of 
piliated forms to epithelial cells in vitro, and incidence of a pilus antigen among 
porcine enteropathogenic E. coli. Infection and Immunity, 1977. 16(1): p. 344-
352. 
43. Isaacson, R.E., et al., In vitro adhesion of Escherichia coli to porcine small 
intestinal epithelial cells: pili as adhesive factors. Infection and Immunity, 1978. 
21(2): p. 392-397. 
44. Kyogashima, M., V. Ginsburg, and H.C. Krivan, Escherichia coli K99 binds to N-
glycolylsialoparagloboside and N-glycolyl-GM3 found in piglet small intestine. 
Archives of Biochemistry and Biophysics, 1989. 270(1): p. 391-397. 
45. Vedantam, P., et al., Binding of Escherichia coli to Functionalized Gold 
Nanoparticles. Plasmonics, 2012. 7(2): p. 301-308. 
46. Stone, R., et al., A Versatile Stable Platform for Multifunctional Applications: 
Synthesis of NitroDOPA-PEO-Alkyne Scaffolding for Iron Oxide Nanoparticles. 
Journal of Materials Chemistry B, 2014. 2: p. 4789-4793 
47. J., S. and R. D.W., Molecular cloning: a laboratory manual, 3rd edn. 2001, Cold 
Spring Harbor Laboratory Press: Cold Spring Harbor. 
48. Chakraborti, S., et al., The molecular basis of inactivation of metronidazole-
resistant Helicobacter pylori using polyethyleneimine functionalized zinc oxide 
nanoparticles. PloS one, 2013. 8(8): p. e70776. 
49. Amstad, E., et al., Influence of Electronegative Substituents on the Binding 
Affinity of Catechol-Derived Anchors to Fe3O4 Nanoparticles. The Journal of 
Physical Chemistry C, 2010. 115(3): p. 683-691. 
50. Sun, S., et al., Monodisperse MFe2O4 (M= Fe, Co, Mn) nanoparticles. Journal of 
the American Chemical Society, 2004. 126(1): p. 273-279. 
51. Davis, K.M., et al., Quantitative measurement of ligand exchange on iron oxide 
nanoparticles via radiolabeled oleic acid. Langmuir, 2014. 30(36): p. 10918-
10925 
 57 
52. Hayden, S.C., et al., Aggregation and interaction of cationic nanoparticles on 
bacterial surfaces. Journal of the American Chemical Society, 2012. 134(16): p. 
6920-6923. 
53. Sharon, N. and I. Ofek, Safe as mother's milk: carbohydrates as future anti-
adhesion drugs for bacterial diseases. Glycoconjugate Journal, 2000. 17(7-9): p. 
659-664. 
54. Jay, C.M., et al., Enterotoxigenic K99 Escherichia coli attachment to host cell 
receptors inhibited by recombinant pili protein. Veterinary Microbiology, 2004. 























Multi-Anchored Glycoconjugate-Functionalized Magnetic 
Nanoparticles: A Tool for Selective Killing of Targeted Bacteria via 
Alternating Magnetic Fields 
[This chapter is taken directly or adapted from work published in Advanced Functional 
Materials journal by Raval et al. (2017); DOI: 10.1002/adfm.201701473. Copyrights 




The emergence of anti-microbial resistance (AMR) has quickly taken hold as one 
of the greatest threats to modern medicine on a global scale, and the ramifications, if not 
dealt with in a timely manner, may be catastrophic. Currently, there are more than 160 
different kinds of antibiotics available for therapeutic purposes [1]. However, unrestricted 
and prolonged usage of antibiotics has resulted in rapid emergence of new strains of 
bacteria that have developed resistance to these drugs and, over time, evolved as multi-
drug resistant microorganisms. Infections caused by such bacterial strains have resulted 
in prolonged hospital stays and an increase in outpatient costs and patient mortality and 
morbidity throughout the world [2]. In a World Health Organization (WHO) global report 
on antimicrobial resistance, it is stated that AMR is a complex global public health 
challenge and that no single or simple strategy will contain the emergence and spread of 
 59 
AMR infectious organisms [3]. A recent study by the US Center for Disease Control and 
Prevention estimates that every year, diseases caused by AMR strains of bacteria infect 
millions of people in the US, and thousands of them die annually due to lack of new 
antibiotics [4]. The emergence of AMR also has an enormous socio-economic impact. A 
2014 report from RAND Europe, estimates the economic cost of AMR to be 
approximately 3.1% of global output gross domestic product (~2.4 trillion US dollars) 
[5]. Although recognized as an immediate issue, antibiotic discovery has declined with 
many major pharmaceutical companies discontinuing their antibiotic development 
programs over the past decade due to low return on investment and difficulties in 
identifying new compounds. This reinforces the need for development of novel 
therapeutic approaches to address the AMR challenges [6-8]. 
Nanoparticles have been a highly investigated area as their properties differ from 
their bulk counterparts. Of these materials, iron oxide has found particular prevalence in 
the biomedical field with use in MRI contrast, drug delivery, cell separation, and cancer 
therapy [9-11]. When an iron oxide particle is subjected to an alternating magnetic field, 
a hysteresis loop is completed in which the area relates to the energy release per cycle 
[12]. By doing this at relatively high frequencies (kHz-MHz), the amount of energy 
transfer is great enough to affect surrounding cells [13]. This phenomenon was 
previously referred to as magnetic hyperthermia due to an observed temperature rise. 
However, recent studies have shown that cell death could be induced in the absence of 
bulk heating of the environment [13, 14]. In seeking a more descriptive term, we and 
others prefer to use the phrase magnetically mediated energy delivery (MagMED) [15, 
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16]. The use of nanoparticles for biological applications requires stringent attention to 
surface chemistry as it affects reactivity, bio-distribution, and stability [9, 17]. Much 
research has been put into optimizing surface chemistries for nanomaterials, with 
poly(ethylene oxide) (PEO) being one of the universally accepted coatings [18]. PEO has 
been shown to prolong circulation time, greatly improve stability in protein and ion-rich 
environments, impart secondary functionality, and render stealth from the immune 
system [18]. Further enhancement in stability may be imparted using a multi-anchored 
catechol as the iron binding moiety [17, 19]. This is highly necessary as desorption of the 
polymer coating is an issue with many biomolecules including phosphonates and 
peptides, which have high affinity for iron oxide [20].  
Though numerous groups have reported using alternate magnetic field along with 
magnetic nanoparticles as an alternative cancer therapy, limited work has been done in 
the same direction for treating bacterial infections [21-23]. More importantly, to the best 
of the authors’ knowledge, no work exploring the use of nanoparticles for selective 
killing of targeted pathogen in mixed-bacterial culture settings has been reported. 
Attachment of bacterial pathogens onto the surface of mammalian cells is one of the 
foremost events in host-pathogen interactions. Several pathogenic bacteria are able to 
adhere to specific host-cell receptors via carbohydrate binding proteins, also called 
adhesins or lectins [24]. These interactions are part of the signal cascade enabling 
bacteria to recognize the environment they are in and then turn on the cascade of 
processes leading to infections [25, 26]. If these binding interactions are 
inhibited/interrupted then the chances of getting infection is greatly reduced [27].  
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The rapid advancement in the fields of nanotechnology and glycotechnology 
offers potentially new therapeutic options for treating bacterial infections. Over the last 
few years, few research groups have studied nanomaterials functionalized with 
multivalent carbohydrate groups and synthetic glycoconjugates for probing bacterial 
lectin-carbohydrate interactions [28, 29]. Attaching these molecules onto the surface of 
nanomaterials has found numerous applications in pathogen detection/targeting,[30] 
mammalian cell-receptor mimicking [31], drug delivery [32], and in anti-adhesion 
therapies [33]. Specifically, carbon nanotubes [34, 35], gold nanoparticles [36, 37], 
diamond nanoparticles [38], polymeric nanoparticles [39], and magnetic nanoparticles 
[40-43] were reported to be bio-functionalized with different carbohydrate 
sugars/glycoconjugates and were utilized for studying lectin-carbohydrate interactions in 
different bacterial species. Given the excellent biocompatibility of using glycoconjugates 
molecules for functionalizing nanomaterials, not many studies have been carried out that 
can specifically detect and differentiate bacterial species in a mixed population both in 
vitro and in vivo. 
Escherichia coli (E. coli) is one of the most common types of bacteria naturally 
occurring in the digestive tract of humans and animals. While most of the E. coli strains 
are harmless to humans and animals, there are few E. coli serogroups that are mainly 
responsible in causing infections. E. coli belonging to the enterotoxigenic (ETEC) group 
is responsible for causing traveler’s diarrhea in humans and bloody diarrhea in neonatal 
calves, pigs and lambs [44-46]. The prevalence of the serogroups and presence of 
adhesins are considered to be the primary factors that facilitate intestinal colonization of 
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ETEC. ETEC adhere to small intestinal microvilli membranes in vivo via adhesins that 
recognizes specific carbohydrate receptors and produce enterotoxins that act on 
enterocytes eventually causing diarrhea [47]. Recently, numerous studies have reported 
an increase in multi-drug resistance of ETEC strains associated with the inclusion of 
growth-promoting antibiotics in animal feed [48, 49]. E. coli K99 (EC K99) is one of the 
commonly found ETEC strains in newborn farm animals responsible for causing 
colibacillosis [50]. EC K99 has unique adhesins that can specifically recognize and attach 
to sialic-acid based glycolipid receptors present on the ileal villus epithelium of the small 
intestine [51, 52]. If these binding interactions are inhibited/interrupted, the chances of 
getting infection are greatly reduced. Our previous studies have shown that nanoparticles 
functionalized with specific sialic-acid derivatives resulted in nanoparticles-induced 
aggregation of EC K99 along with excellent biocompatibility [36, 41].  
In this study, it is hypothesized that multi-anchored magnetic nanoparticles 
conjugated with sialic-acid moieties that mimic host-cell receptors specific for EC K99 
adhesins, would induce rapid clustering of EC K99 in the presence of these nanoparticles, 
and when such bacteria-nanoparticles aggregates are exposed to AMF, it would result in 
enhanced and selective inactivation/killing of EC K99. Our results demonstrate a 
clinically significant ~3-log reduction in CFU [53] of EC K99 in the presence of GM3-
MNPs used in conjunction with AMF. To our knowledge, it is for the first time that 
sialic-acid derived glycoconjugate functionalized magnetic nanoparticles have been 
employed for specific killing of target bacteria in the presence of AMF. This study serves 
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as proof-of-concept that a high degree of selective bacterial killing can be obtained 
without using traditional antibiotics. 
 
2. Experimental Section: 
Synthesis of Magnetite Nanoparticles: Magnetite nanoparticles were synthesized 
via thermal decomposition of an organometallic precursor in a high boiling point organic 
solvent [54]. Iron (III) acetylacetonate (Alfa Aesar, 99%) (1.074g) was combined in a 3-
neck round-bottom with oleic acid (Alfa Aesar, 90%) (15ml) serving as both the solvent 
and the stabilizing ligand. The vessel was initially purged with N2 after which flow was 
adjusted to 0.1 L/min ensuring an inert environment.  The vessel was then heated to 
350°C and left to react for 3 hours. At 3 hours, the reaction was quenched by removing it 
from heat, and left to cool under inert atmosphere. The resulting particles were dispersed 
in minimal hexanes and precipitated using a mixture of 3:1 ethanol (Fisher, Anhydrous) 
to acetone (Alfa Aesar, 99.5%) (x3). Particles were dispersed in toluene (VWR, 99.5%) 
and run through an organic based GPC column (Bio-rad S-X polystyrene beads) to 
further remove excess oleic acid ligand [55]. TEM and size analysis was then done on the 
particles to ensure size specificity. 
Synthesis of Alkyne-PEO-PAA-Dopamine [19]: Poly(ethylene oxide) (PEO) 
synthesis: Ethylene oxide (Sigma Aldrich, 99.9%) distilled into a high pressure Parr 
reactor. Na-benzylphenone still dried tetrahydrofuran (THF, EMD Millipore, 99.9%) was 
injected along with a predetermined amount of an anionic initiator potassium bistrimethyl 
silyl amide (Sigma Aldrich, 1M in THF). The reaction was allowed to run for 72 hours 
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and was subsequently terminated by opening the reactor to atmosphere. The synthesized 
PEO was precipitated with diethyl ether (VWR, 99.9%) and washed (3x) by dispersing it 
in chloroform, precipitating the polymer, centrifuging it at 15,000 RCF for 10 minutes 
and pouring off the residual supernatant. The PEO was then dried under vacuum 
overnight. HNMR was performed to calculate molecular weight as well as to confirm the 
presence of the protected amine end-group.  
Under dry N2 atmosphere, hetero-functional PEO and sodium hydride (Sigma 
Aldrich, 95%), in slight excess, were dissolved in dry THF. This was allowed to react for 
30 minutes before an excess of propargyl bromide (Sigma Aldrich, 80% in toluene) was 
added drop-wise to the solution over 15 minutes. Once all of the propargyl bromide was 
added, the solution was allowed to stir for 12 hours at room temperature. The polymer 
was then purified by dissolution in chloroform and precipitation with diethyl ether (x3) 
and dried under vacuum for 12 hours. HNMR was performed to confirm the presence of 
an alkyne. 
Deprotection of the trimethyl silyl group was done in 1M hydrochloric acid 
(VWR) in methanol (VWR, 99+%) and allowed to react for 4 hours. The polymer 
methanol solution was diluted with DI water and the deprotected PEO was extracted (3x) 
with 50ml chloroform from which it was precipitated with diethyl ether and dried under 
vacuum. HNMR was performed to confirm the loss of the trimethylsilyl group. 
Coupling of the PEO to the poly(acrylic acid) (PAA, Sigma Aldrich Mn=1,800) was done 
by dissolving both in dry N,N-dimethylformamide (DMF, Sigma Aldrich, 99.8%) in a 5:1 
ratio. To this 1.1 excess (N-(3-dimethylaminopropyl)-N’-ethylcarodiimide hydrochloride 
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(EDC, TCI, 98%) as well as catalytic amounts of 4-(dimethylamino)pyridine (DMAP, 
Alfa Aesar, 99+%) were added. The solution was allowed to stir for 12 hours. The 
solution was filtered, further purified by dissolution in chloroform following precipitation 
with diethyl ether (x3) and then dried under vacuum. HNMR was done to confirm PEO-
PAA coupling. 
Attachment of the anchor group: Dopamine hydrochloride (Alfa Aesar, 99%) was 
dissolved in DMF along with a 10% molar excess of triethylamine (Alfa Aesar, 99%) and 
allowed to stir for 30 minutes. In a separate round-bottom the PEO-PAA was dissolved in 
DMF along with EDC and catalytic amounts of DMAP. To this the dopamine 
hydrochloride solution was added and the combined solution was allowed to stir for 12 
hours. The solution was then filtered, purified by dissolution in chloroform then 
precipitated in diethyl ether. The final product was dried under vacuum and analyzed via 
HNMR and IR to confirm the presence of the catechol. 
Ligand Exchange [17]: Both magnetite nanoparticles as well as the PEO-PAA-
dopamine were suspended separately in 5ml of chloroform. The particles were at an 
approximate concentration of 3mg/ml of Fe and the polymer at approximately 40mg/ml. 
The polymer was then transferred to a scintillation vial capped with a septum and placed 
in a sonication bath. The bath was turned on and over the course of 15 minutes the 
magnetic nanoparticle solution was injected into the polymer solution. Once injection 
was finished, the combined solution was allowed to further sonicate for 15 minutes. The 
solution was then removed and put on a shaker table for 72 hours. The chloroform was 
then removed via rotary evaporator and further dried under vacuum. Deionized water (DI 
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H2O) was then added and the vial was sonicated to help mediate suspension into the 
water. The water-based particles were then filtered through a 0.2-micron nylon filter to 
ensure large aggregates were not present. The solutions were then run through a GPC 
column (Bio-Rad P polyacrylamide beads) to separate excess polymer from the water 
dispersible particles. 
Click Chemistry [56]: The Cu(I) catalyzed Huisgen 1,3-dipolar cyclo-addition 
between the terminal polymer alkyne and the azido-GM3 was done in the aqueous phase 
with the azido-GM3 being the limiting reagent. A 2 mol% solution of Cu(II) sulfate 
(Sigma Aldrich, 99%) was combined with equivalent molar amounts of the THPTA 
(synthesized according to Hong et al.)  Cu chelating ligand and let to react for 10 minutes 
[57]. This was then transferred into the aqueous alkyne-particle suspension and the azide-
GM3 was then added. After both additions a 10mol% aqueous solution of (+)-sodium L- 
ascorbate (Sigma Aldrich 98+%) was added to facilitate the reduction of Cu(II) to Cu(I). 
The click reactions were left at room temperature for 12 hours, and were then purified 
using size exclusion chromatography [55]. 
Dynamic Light Scattering (DLS) and Zeta Potential Measurements: DLS was 
performed on the PEO-coated and GM3-coated magnetic nanoparticles to determine their 
hydrodynamic radius. The nanoparticle suspensions were diluted in water and placed into 
a cuvette. Three readings were taken at 25°C using Malvern Zetasizer Nano ZS to 
determine the intensity average size distribution and z-average diameter. Zeta-potential 
measurements of these nanoparticle suspensions were also determined using the same 
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instrument. The suspensions were diluted with water and added into zeta-cell and three 
measurements were taken at 25°C. 
Fourier Transform Infrared Spectroscopy (FTIR): Fourier transform infrared 
(FTIR) spectroscopy microscopy was done using a Thermo-Nicolet Magna 550 FTIR 
spectrometer equipped with a Thermo-NicPlan FTIR microscope. 16 Scans were done for 
both the sample and the background. Samples were prepared by dropping a small amount 
of the water suspended sample on a germanium plate and left to dry under a heat lamp for 
20 minutes. FTIR was done on the resulting films. 
Iron Concentration Determination: 50 µl of magnetite suspension was dissolved 
in concentrated HCl, reduced and complexed with 1,10-phenanthroline (Sigma-Aldrich, 
99%). UV-VIS was then performed to determine the amount of iron in the known volume 
[58, 59]. 
AMF Treatment of Bacterial Strains in the Presence of MNPs: As reported in 
our previous study [41], E. coli K99 (EC K99) was transformed with plasmid pGREEN 
(Carolina Biological Supply Company, NC, USA) carrying ampicillin-resistance marker 
gene. Avirulent E. coli O157:H7 strain B6914 (EC O157) was modified to be rifampicin 
resistant (100 µg/ml; TCI America, OR, USA) through gradient-plate technique as 
previously described [60]. EC K99 strain was routinely grown in tryptic soy broth/tryptic 
soy agar (TSB/TSA; EMD Millipore, MA, USA) supplemented with ampicillin (100 
µg/ml; TCI America, OR, USA) and EC O157 strain was grown in tryptic soy 
broth/tryptic soy agar (TSB/TSA) supplemented with rifampicin (100 µg/ml). For AMF 
treatment experiments, bacterial cultures were grown overnight under shaking conditions 
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(250 rpm) at 37°C in TSB supplemented with appropriate antibiotics. Later, the bacterial 
cells were washed and centrifuged thrice in 1X sterile phosphate buffer saline (PBS). 
Approximately, 5 x 107 CFU of bacterial cells were suspended in 1X PBS based on 
optical density (OD600) readings. Both the bacterial strains were mixed with different 
types of MNPs and at different concentrations of MNPs in a sterile microcentrifuge tube 
and this mixture was incubated at room temperature for 30 minutes under gentle shaking 
conditions to facilitate the binding interactions between bacterial adhesins and MNPs 
[41]. At the end of incubation time-period, the mixtures of MNPs and bacteria were 
transferred to sterile glass vial. This vial was then placed in chamber of the alternate 
magnetic field generating instrument (EasyHeat Induction Heating System - 
Ameritherm©) that is covered with 5-turn induction coil, which was connected to 
polycarbonate recirculating water-bath for maintaining the sample temperature (37°C) 
[61]. A fiber-optic temperature probe (Neoptix™) was inserted inside this chamber to 
continuously monitor the temperature. The working conditions of the AMF instrument 
for the experiments were as follows: 480 Amps current, 207KHz frequency and magnetic 
field strength of 31 KA/m. The field was measured using an AC magnetic field probe 
(AMF Life Systems, Auburn Hills, MI). The vial containing the mixture of MNPs and 
bacteria was then exposed to AMF treatment for different durations (30, 60, and 120 
minutes). Different groups of control experiments were as follows: 1) mixture containing 
only bacterial strains suspended in 1X PBS; 2) mixture containing bacteria and MNPs but 
no AMF exposure. After AMF treatment, the above-mentioned mixture was serially 
diluted in 1X sterile PBS and 100 µl of sample from each dilution tube was spread-plated 
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onto sterile TSA petri plates supplemented with appropriate antibiotics. Later, the TSA 
plates were incubated overnight at 37°C. Finally, the grown colonies on the TSA plates 
were counted and compared with control group plates and the reduction in colony counts 
was expressed as colony forming units per ml.  
AMF Treatment of Mixed Bacterial Cultures in the Presence of MNPs: To 
determine the targeted specificity of GM3-MNPs against EC K99 in mixed-culture 
conditions, both the strains of EC K99 (concentration - 5 x 107 CFU) and EC O157 
(concentration - 5 x 107 CFU) were mixed in a single microcentrifuge tube. GM3-MNPs 
(650 µg/ml) were added to this mixture and the tube was incubated for 30 minutes at 
room temperature under gentle shaking conditions. Later, AMF treatment (time - 120 
minutes) was applied to this tube as mentioned earlier. Control groups included 1) adding 
PEO-MNPs to mixture containing both strains of bacteria in the same tube and 
exposing/not exposing them to AMF; 2) adding GM3-MNPs to tube containing both 
bacterial strains but no AMF; 3) AMF exposure to tube containing only bacterial strains 
and no MNPs. Post-treatment, this mixture was serially diluted in 1X PBS and 100 µl of 
each dilution was spread plated in triplicates onto TSA plates supplemented with 
appropriate antibiotics. The petri plates were incubated overnight at 37°C and CFU 
reduction was compared to control group plates.  
Transmission Electron Microscopy (TEM) of Bacterial Strains: TEM imaging 
of bacteria was performed in order to study the interaction of MNPs and bacterial cell-
surface. The samples were prepared according to modified protocol [41, 62]. Post AMF 
treatment of bacterial cells (MNPs concentration - 650 µg/ml), the mixture samples were 
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removed from the glass vial and centrifuged at 7000 x g for 5 minutes. Later, the 
supernatant containing unbound MNPs was removed and the pellet was washed with 1x 
PBS in repetitive centrifugation cycles (3 times). After the final wash, the pellet 
containing MNPs and bacteria was fixed in cacodylate-buffered glutaraldehyde (3%, 
pH~7.2; Electron Microscopy Sciences, PA, USA) at 4°C for 12 hours. Subsequently, the 
sample was again washed in the cacodylate buffer thrice. 5 µl of the sample was dropped 
onto carbon-coated copper grid and was allowed to air dry for 4 hours. Finally, the 
sample was stained with 2% uranyl acetate (Electron Microscopy Sciences, PA, USA) 
solution for 15 seconds and blotted dry with filter paper. TEM images were taken on 
Hitachi H-7600 at 120 KV accelerating voltage and magnification ranging from 10,000X 
to 200,000X. 
Bacterial Live/Dead Fluorescence Assay: To qualitatively determine the cell 
membrane integrity of bacterial cells, Live/Dead fluorescence assay were performed 
using BacLight™ Bacterial Viability Kit (L7007, Molecular Probes, Invitrogen, OR, 
USA). Freshly grown cells of EC K99 and EC O157 (5 x 107 CFU) in 1X PBS were 
mixed with PEO-MNPs and GM3-MNPs (Concentration - 650 µg/ml) separately in 
different microcentrifuge tubes. The mixture was allowed to incubate at room 
temperature for 30 minutes with gentle mixing after every 5 minutes. The tubes were then 
exposed to AMF therapy for 120 minutes. The samples were then prepared according to 
manufacturer’s protocol. Later, both fluorescent dyes i.e. SYTO 9 and Propidium Iodide 
were added to the samples. Finally, the samples were viewed under fluorescence 
microscope under different filters (SYTO 9 - Excitation/Emission - 485/510 nm; 
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Propidium Iodide - Excitation/Emission - 485/630 nm) at 400X magnification. The 
images obtained under different filters were merged in ImageJ software (NIH, USA). 
Control group samples were not exposed to MNPs/AMF.  
Microbial ATP Cell-Viability Assay: To measure the overall intracellular ATP 
levels of bacterial species (EC K99 and EC O157) before and after AMF treatment in the 
presence/absence of MNPs (concentration - 650 µg/ml, AMF treatment time - 120 
minutes), microbial BacTiter-Glo™ (Promega, Madison, WI) assay kit was used [23]. 
The assay was performed according to manufacturer’s protocol with a small modification 
for samples containing MNPs. After AMF treatment of bacteria in the presence of MNPs, 
the samples were centrifuged at 10,000 x g for 5 minutes. The supernatant containing 
unbound MNPs was removed and the resultant pellet was washed with 1X PBS thrice in 
subsequent centrifugation cycles. Finally, the samples were suspended back in 1X PBS 
and the entire assay was performed in 96-well white-flat bottom plates (Corning®) in 
triplicates. Also, wells containing MNPs without any bacterial cells were used as control 
blanks to check for MNPs interference with the assay reagent, if any. At the end of this 
assay, the plate was read in a micro-plate reader with luminescence capability (Synergy 
Hybrid H1, Biotek®) and the obtained results were expressed in relative luminescent units 
(RLUs).    
Statistical Analysis: All the statistical analysis was performed using Graphpad 
Prism software (V 5.0, CA, USA). All the experiments were done in triplicates and data 
are expressed as Mean±SD. Statistically significant differences between the groups were 
evaluated by performing ANOVA. Post hoc group comparisons were calculated through 
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Bonferroni post-tests. Results showing P values of ≤0.05, <0.01, and <0.001 were 
considered to be statistically significant.  
3. Results and Discussion: 
3.1. Synthesis of GM3-MNPs: 
Magnetite nanoparticles were synthesized using a one-pot thermal decomposition 
of iron (III) acetylacetonate and oleic acid [1, 2]. Particles had an average diameter of 
23.7 nm with a standard deviation of 1.55 nm (Figure 3.2 A and B). The moment vs. field 
(MvH) (Figure 3.3) measurement was done on the particles to confirm the super-
paramagnetic behavior of the MNPs. Polymer design was based on work by Stone et al. 
where a multi-anchored binding approach showed increased stability in comparison to 
polymer ligands with a single binding moiety (figure 3.1) [3].  
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Figure 3.1 Left: 1) Anionic ring opening of ethylene oxide, 2) alkyne functionalization with propargyl bromide, 3) 
deprotection of primary amine, 4) coupling of PEO to PAA, 5) coupling of dopamine hydrochloride to the PEO-PAA. 
Right: Click reaction between polymer coated particles and GM3 molecule. 
 
Figure 3.2 Magnetite nanoparticles as synthesized before functionalization with PEO-PAA-dopamine polymer. A – 
Representative TEM image of the particles. B – Histogram depicting the particle size distribution. 
 
Figure 3.3 Moment vs. Field (MvH) loop showing the superparamagnetic behavior of the magnetite nanoparticles 
(Msat ~ 53 emu/g Fe). 
In this work, however, the chosen catechol was not nitroDOPA but dopamine. HNMR of 
the polymer was used to confirm both the structure and molecular weight of the PEO-
PAA-dopamine macromolecule (Figure 3.4).  By using the multi-anchored approach, the 
stability in salt and protein buffer solutions is retained even when using dopamine as the 
A B 
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anchoring group [4, 5]. Hydrodynamic diameter and zeta potential of the PEO-MNPs 
before and after click-coupling of GM3 are reported in Table 3.1.  
 
Figure 3.4 HNMR of the final PEO-PAA-dopamine - PAA backbone protons at 1.39 ppm - 1.08 ppm. Alkyne protons 
at 4.18 ppm and 2.42 ppm. PEO repeat protons at 3.62 ppm. Dopamine aromatic proton signal partially masked by the 
CDCl3 peak, with alkane protons showing up at 2.8 ppm. Reference was tetramethylsilane at ~0 ppm.  
 
 








PEO-MNPs 78.8 -8.73 
GM3-MNPs 88.8 -7.68 
 
Table 3.1 Dynamic light scattering and zeta-potential measurements - Hydrodynamic diameter and zeta potential as 
measured by dynamic light scattering before and after GM3 conjugation. 
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The specific absorption rate (SAR) value for the MNPs was measured to be 53.4 W/g 
(bulk temperature rise of solution from 37°C to 42°C), which is similar to the value for 
magnetite reported by Ma et al [6]. The increase in the hydrodynamic diameter indicates 
the GM3 glycoconjugate was successfully coupled to the PEO-MNPs. Attenuated total 
reflectance Fourier transformed infrared spectroscopy (ATR-FTIR) also confirmed the 
GM3 coupling went to completion with the disappearance of the azide peak from GM3 at 
~2110 cm-1 and the appearance of a broad alcohol peak in the GM3-MNPs spectrum from 
3620-3170 cm-1 (Figure 3.5) [7]. 
 
Figure 3.5 FTIR spectra of particles before GM3 conjugation (A), GM3 molecule (B), and after conjugation (C). The 




3.2 MagMED Inactivation of Bacteria: 
The efficacy of GM3-MNPs for specific inactivation of ETEC K99 via MagMED 
was compared to that of enterohaemorrhagic Escherichia coli (EHEC) O157:H7 strain 
since the two strains showed different receptor-binding specificities and EHEC O157:H7 
strains are rarely harbored by pigs [8]. Another E. coli strain ORN178 expressing 
mannose-binding type-1 fimbrial FimH adhesins [9-13] was also evaluated and served as 
a negative control (data not shown). The MagMED inactivation of bacteria was assessed 
using a colony forming unit (CFU) reduction assay to determine the number of viable 
cells (CFUs) remained after treatment. 
 
3.2.1 MagMED Inactivation of EC K99: 
The efficacy of AMF mediated killing of the target bacteria, EC K99, in the 
presence of GM3-MNPs in a concentration- and time-dependent manner was evaluated. 
GM3-MNPs were mixed with EC K99 and incubated at room temperature for 30 minutes 
to facilitate the binding between GM3 molecules present on the surface of GM3-MNPs 
and adhesin molecules of EC K99 [7]. PEO-MNPs were used as an internal control group 
to evaluate the role of the targeting moiety GM3. The magnetic field and frequency used 
in the AMF therapy remained constant for all treatment groups (31 kA/m and 207kHz). 
Figure 3.6 A shows the final counts of CFU/ml of EC K99 after treatment. The reduction 
in CFU/ml was found to be both time and MNPs concentration dependent. After 30 
minutes of AMF treatment, ~1-log reduction in CFU/ml of EC K99 was observed at a 
particle concentration of 650 µg Fe/ml. After 60 minutes of AMF treatment, a significant 
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~2-log reduction of EC K99 (p<0.01) was observed for both 280 µg Fe/ml and 650 µg 
Fe/ml concentrations of GM3-MNPs. Finally, at the end of 120 minutes of AMF 
treatment, an extremely significant ~3-log reduction in CFU/ml of EC K99 (p<0.001) 
was achieved with particle concentrations of 650 µg Fe/ml. Moreover, no significant 
killing of EC K99 was observed in experimental groups not exposed to AMF (Figure 3.7 
A) indicating the non-toxicity of PEO-MNPs and GM3-MNPs to EC K99.  
 
Figure 3.6 Colony Forming Unit (CFU) of E. coli strains after AMF treatment at different concentrations of MNPs and 
different time-intervals; A - CFU/ml of EC K99 after AMF treatment; B - CFU/ml of EC O157 after AMF treatment. 
Data is expressed as Mean ± SD (n=3); Statistical analysis – Analysis of Variance (ANOVA); * p-value <0.05,  ** p-




Figure 3.7 CFU/ml assay to determine viability of E. coli strains in the absence of AMF at different concentrations of 
MNPs and at different time-intervals: A - CFU/ml of EC K99 in the absence of AMF; B - CFU/ml of EC O157 in the 
absence of AMF. Data is expressed as Mean ± SD (n=3); Statistical analysis – Analysis of Variance (ANOVA). 
 
Thus, targeted approach in AMF exposure can explain such effective reduction in 
CFU/ml of EC K99. Several research studies have shown similar results in reduction of 
bacterial population through antibody-targeted photo-inactivation process via near-
infrared laser (NIR) in the presence of nanoparticles in both in vitro and in vivo settings 
[14-16]. In our previous work, we have shown that sialic-acid sequences of GM3 
molecule (Neu5Ac(α2-3)-Gal-(β1-4)Glcβ-sp) can specifically interact with S-type 
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fimbrial proteins/adhesins present on the outer surface of EC K99 and induce rapid 
clustering of EC K99 [7, 17]. The presence of FanC, a major protein sub-unit present in 
S-type fimbriae, is primarily responsible for the specific attachment of EC K99 onto the 
ganglioside receptors, which are present on the host-cell surface [18]. Therefore, it is 
likely that GM3-MNPs-induced bacterial aggregation plays a major role in the applied 
method. Since GM3-MNPs are attached to or are in extremely near vicinity of EC K99, 
one can expect to see increased delivery of energy from the particles into the bacterial 
cells. Some reports have also suggested highly localized temperature increase taking 
place in the biological systems in the presence of MNPs when using AMF [19-21]. For 
example, Huang et al. functionalized the surface of MNPs with fluorophores that act as 
molecular temperature probes while remotely activating ion channels/neurons in the 
presence of AMF [22]. Also, the observed drug release due to phase changes in the 
polymer near the surface of the particle suggests a local temperature increase [23]. In 
these studies, too, the overall temperature of bulk particle suspensions remained constant 
or increased marginally. However, the exact mechanisms of how energy from the particle 
interferes with these pathways are still unknown and are in need of better 
characterization.  
In the present study, the experimental group comprising of 140 µg Fe/ml that 
underwent AMF treatment did not show significant reduction in CFU/ml of EC K99 after 
120 minutes of exposure. One possible explanation for this might have to do with the 
number of particles present in different concentrations of the GM3-MNPs. The lowest 
concentration group would have the least amount of MNPs. Thus, they might not be able 
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to efficiently deliver the energy of the MNPs into the bacterial cells. PEO-MNPs at all 
concentrations and all time-points did not induce significant decrease in the colony 
counts of EC K99. 
3.2.2 MagMED Inactivation of EC O157: 
Figure 3.6 B shows the overall reduction in CFU/ml of EC O157 after exposure to 
AMF in the presence of PEO-MNPs or GM3-MNPs. A ~1-log reduction in CFU/ml was 
observed with both PEO-MNPs and GM3-MNPs at particle concentration of 650 µg 
Fe/ml for 60 and 120 minutes. All other MNPs concentrations and time-points showed no 
significant reduction in colony counts of EC O157. No reduction in CFU/ml of EC O157 
was observed in the absence of AMF (Figure 3.7 B) indicating the non-toxicity of PEO-
MNPs and GM3-MNPs to EC O157. Several groups have observed certain degree of 
non-specific electrostatic interactions occurring between bacteria and nanoparticles when 
mixed with relatively higher concentrations of nanoparticles [24, 25]. Hence, it is 
possible that due to such non-specific interactions along with high MNPs-to-bacteria 
ratio, few MNPs might come in contact or close proximity with EC O157 resulting in 
delivery of some magnetic energy into these cells causing a limited ~1-log reduction in 
CFU. Bacterial control groups exposed to AMF in the absence of MNPs showed no 
changes in the overall CFU/ml after 120 minutes of exposure (Figure 3.8 A and B) 
indicating the non-lethal effect of AMF. 
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Figure 3.8 Survival rate of E. coli strains at 37°C in the absence of MNPs at different time-intervals: A - CFU/ml of 
EC K99 in the absence/presence of AMF; B - CFU/ml of EC O157 in the absence/presence of AMF. Data is expressed 
as Mean ± SD (n=3); Statistical analysis – Analysis of Variance (ANOVA). 
 
Recently, Nguyen et al. conducted a similar type of study wherein they showed 
that iron-oxide nanoparticles could rapidly induce biofilm dispersal in Pseudomonas 
aeruginosa (P. aeruginosa) through application of an alternating magnetic field [26]. 
Their study showed rapid increase in the temperature of buffer solution when 
nanoparticles were mixed with them and exposed to magnetic field. Similarly, another 
study reported 4-log reduction in biofilm of P. aeruginosa when exposed AC magnetic 
field in the presence of iron-oxide nanoparticles [27]. The authors have attributed this 
reduction in biofilm due to quick increase in bulk temperature of the system through 
magnetic hyperthermia. Thomas et al. used magnetic fluid hyperthermia in the presence 
of carboxylic-acid stabilized iron-oxide nanoparticles and achieved ~7-log reduction in 
population of Staphylococcus aureus [28]. In all of the aforementioned studies, the 
killing/inactivation of bacterial species/biofilms was attained solely due to drastic 
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increase in the bulk temperature of the working system through nanoparticles and 
hyperthermia. It would be worthwhile to note that the aforementioned studies were 
conducted in the presence of relatively high concentrations of MNPs (ranging from 1 
mg/ml to 50 mg/ml) and higher instrument frequencies (e.g., up to 1.05 MHz). Using 
such high concentrations of MNPs in humans might cause serious concerns with regard 
to toxicity of MNPs. Also, none of the above listed studies utilized any kind of targeting 
moiety on nanoparticles for attaining specificity. On the other end, this work 
demonstrates significant killing of EC K99 at much lower concentrations (maximum 
concentration - 650 µg Fe/ml) and at relatively benign frequencies (i.e., 207 kHz). These 
results further support our hypothesis that the combination of magnetic fields and 
presence of GM3-MNPs are responsible for reduction in CFU/ml of EC K99 via targeted 
AMF therapy. The reported CFU reduction within 120 minutes (i.e., 3-log in 2 hours) 
treatment compares favorably to conventional antibiotic treatments. For examples, Silva 
et al. reported that ciprofloxacin at concentrations corresponding to 1x MIC (Minimal 
Inhibitory Concentration) reduced E. coli population by 1-log over a 24-h study while at 
2x and 4x times the MIC value, they observed a ~2.5-log reduction in the first 2 hours 
and a 4-log reduction after 24 hours of treatment [29]. In a similar study, Drago et al. 
observed no reduction of E. coli population at 1x MIC with levofloxacin or ciprofloxacin 
over a 24-h period while a 2-log and 3-log reduction at 4x MIC was observed 3 hours and 
24 hours after treatment, respectively [30]. It is conceivable that with fine-tuned 
MagMED treatment regimen, it is possible to improve the treatment outcomes of 
infections caused by multiple-drug resistant bacteria. 
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As mentioned earlier, a moderate temperature increase (37°C to 42°C) was 
observed in the bulk particle suspension while measuring SAR values in the presence of 
magnetic field. To prove that the significant log-reduction of EC K99 is not due to 
temperature increase alone, a CFU/ml assay on both the E. coli strains at elevated 
temperature of 43°C was performed. The bacterial strains were incubated with PEO-
MNPs and GM3-MNPs for 120 minutes and this mixture was kept inside the holding 
chamber of the AMF instrument by maintaining a constant temperature of 43°C for 120 
minutes in the absence of magnetic field. As seen in Figure 3.9 A and B, no significant 
changes in CFU/ml of EC K99 and EC O157 were observed after exposing the bacteria to 
MNPs and at elevated temperatures for 120 minutes. This strongly suggests that 
inactivation of the bacteria cannot be attributed to temperature alone. 
 
Figure 3.9 Evaluating the effect of temperature increase on killing-rate of E. coli strains in the absence of AMF (time - 
120 minutes): A - Killing-rate of EC K99 at 37°C/43°C in the presence of MNPs (concentration - 650 µg Fe/ml); B - 
Killing-rate of EC O157 at 37°C/43°C in the presence of MNPs (concentration - 650 µg Fe/ml). Data is expressed as 
Mean ± SD (n=3); Statistical analysis - 2-Way Analysis of Variance (ANOVA). 
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3.2.3 MagMED Inactivation of EC K99 and EC O157 in Mixed-Culture: 
Pathogens interact with host in a heterogeneous environment; the efficacy of 
utilizing MagMED for killing of the target bacteria EC K99 was evaluated in a mixed-
culture condition. Both strains of the E. coli cultures were mixed in the same container at 
equal concentrations and added either the GM3-MNPs or the PEO-MNPs at a maximum 
concentration of 650 µg Fe/ml. These mixtures underwent the same AMF exposure as 
described earlier for 120 minutes and the CFU/ml reduction assay was done to determine 
the inactivation rates of both strains of E. coli. As seen in Figure 3.10 A, a significant 
~2.5-log reduction (p<0.001) in CFU/ml of EC K99 in the presence of GM3-MNPs and 
AMF exposure was observed. The other mixed culture containing PEO-MNPs did not 
show significant difference in CFU/ml numbers compared to controls in the 
absence/presence of AMF. In addition, ~1-log reduction (p<0.05) in CFU/ml of EC O157 
was seen when the mixed-cultures were added with PEO-MNPs or GM3-MNPs and 
underwent AMF treatment for 120 minutes (Figure 3.10 B). This reduction in CFU/ml of 
EC O157 is comparable in both mixed-culture and pure-culture experiments. Compared 
to CFU/ml assay results of EC K99 in pure bacterial culture experiments where a ~3-log 
reduction was observed, the results obtained from mixed-culture experiments showed a 
~2.5-log reduction. This minor difference could be the result of a change in nanoparticle-
to-bacterium ratio in mixed-culture experiments. Since the nanoparticle-to-bacterium 
ratio was reduced by half under mixed-culture settings, the probability of GM3-MNPs 
interacting with EC K99 as well as EC O157 is also slightly reduced than in pure culture 
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settings. To the best of our knowledge, this is the first report wherein killing of targeted 
bacterial strains via MagMED has been demonstrated in mixed-culture settings. 
 
Figure 3.10 Colony Forming Unit (CFU) of E. coli strains in mixed-culture conditions exposed to AMF for 120 
minutes in the presence of MNPs (650 µg Fe/ml); A - CFU/ml of EC K99 after AMF treatment; B - CFU/ml of EC 
O157 after AMF treatment. Data is expressed as Mean ± SD (n=3); Statistical analysis - 2-Way Analysis of Variance 
(ANOVA); * p-value <0.05, ** p-value <0.01, and *** p-value <0.001. 
3.3 Investigating Interactions between GM3-MNPs and EC K99 via Transmission 
Electron Microscopy (TEM): 
One of the many causes for inactivation/killing of bacterial cells could be due to 
physical damages of bacterial cell membrane that results from the presence of different 
types of nanoparticles [31, 32]. In order to investigate the bacterial-nanoparticle 
interactions between GM3-MNPs and EC K99, TEM analysis on the samples was 
performed before and after AMF exposure. Since the maximum reduction in CFU/ml of 
EC K99 was achieved in the presence of 650 µg Fe/ml MNPs after 120 minutes, the same 
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experimental conditions to investigate if AMF exposure can exert any specific 
morphological changes on the bacterial cell membrane of EC K99 was followed.  
Visualizing TEM images, highly specific interactions taking place between GM3-MNPs 
and outer membrane of EC K99 was observed. Figure 3.11 B shows the extent of GM3-
MNPs specifically attached to EC K99. The entire cell-surface of the bacteria was 
covered with GM3-MNPs before applying AMF. There was no visible morphological 
change seen on the bacterial cell surface of EC K99, which could also indicate that the 
nanoparticle system does not have an apparent inherent toxicity by itself towards 
bacteria.  
 
Figure 3.11 TEM images of GM3-MNPs induced bacterial membrane damage of E. coli strains: A, B, E, F - Before 




Also, GM3-MNPs induced bacterial aggregation of EC K99 was clearly visible in TEM 
images (Figure 3.12 B). In contrast, after applying AMF, the cell structure of EC K99 
was seen to be extremely damaged as seen in Figure 3.10 D. Please also note that the 
diameters of EC K99 were reduced to less than 0.5x0.25 µm from the typical 1x0.5 µm. 
The nanoparticles were found internalized in cells of EC K99 after rupturing the cell 
membrane. Concurrent findings were also reported in a few studies with regard to 
destruction of bacterial cell membrane via targeted photo-thermal lysis in the presence of 
nanoparticles [33, 34]. Even after AMF exposure, GM3-MNPs were found to remain 
attached onto bacterial cell debris, which suggests strong binding interactions between 
GM3-MNPs and adhesin molecules of EC K99 present on the bacterial cell surface. 
Interestingly, it was observed that both the polar ends of EC K99 were found to be much 
more deformed and broken (Figure 3.12 A and B). However, not much damage was seen 
towards the horizontal length of EC K99. A large quantity of cell membrane debris was 
observed in the TEM analysis suggesting that EC K99 would have undergone thermal 
lysis after AMF exposure possibly due to highly localized temperature increase. 
Moreover, both PEO-MNPs and GM3-MNPs did not show any substantial attachment to 
EC O157 cells (Figure 3.11 E to H). Even the cell membrane morphologies looked 
similar to control group cells that were exposed to AMF without any MNPs. Thus, the 
TEM analysis and CFU/ml assays support our initial findings regarding the specific 
interactions occurring between GM3-MNPs and EC K99 and that GM3-MNPs found on 
bacterial surface of EC K99 play an important role in lysing the bacterial cells 
(bactericidal) when exposed to AMF. 
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Figure 3.12 TEM imaging of EC K99 cells after AMF treatment in the presence of GM3-MNPs: A - EC K99 cells 
showing lysis/breakage of their polar ends (Scale bar - 100 nm); B - EC K99 cells showing aggregation and breakage 
induced by presence of GM3-MNPs and AMF (Scale bar - 500 nm). Magnification ranges between 50,000X to 
150,000X. 
3.4 Bacterial Live/Dead Fluorescence Assay:  
One of the common assays employed to check the membrane integrity of bacterial 
cells is to use propidium iodide dye [35]. Since the TEM analysis showed extensive 
membrane damage of EC K99 cells after AMF treatment, to further support these results, 
bacterial live/dead assays were performed. E. coli strains, after AMF exposure in the 
presence of MNPs, were stained using mixture of SYTO 9 and propidium iodide dyes. 
SYTO 9 is a green-fluorescent dye that stains both live and dead bacterial cells by 
entering inside them. Conversely, propidium iodide can only permeate those bacterial 
cells whose cell membrane structures have been compromised and stains them red. For 
this assay, the bacterial strains were mixed with different types of MNPs. Figure 3.13 




Figure 3.13 Live/Dead Staining Assay using SYTO 9 and Propidium iodide dyes. Both strains EC K99 and EC O157 
are stained with mixture containing the above-mentioned dyes. The bacterial strains were initially mixed with PEO-
MNPs and GM3-MNPs (concentration - 650 µg Fe/ml) and then exposed to AMF treatment for 120 minutes. Live 
bacterial cells appear green in color and dead cells appear red in color. All the images are merged together for both 
green and red channel filters of the microscope. A, B, E, and F represent E. coli cells incubated with MNPs but without 
AMF treatment. C, D, G, and H represent E. coli cells incubated with MNPs in the presence of AMF. Magnification - 
400X, Scale bar - 100 µm.  
 
As clearly seen in Figure 3.13 D, more than 95% of EC K99 cells were stained 
red in color after exposure to AMF in the presence of GM3-MNPs. This proves that 
indeed EC K99 cells experienced extensive cell membrane damage due to AMF. Also, 
~50% of EC O157 cells were stained red which suggests partial membrane damage 
(Figure 3.13 G-H). In contrast, both E. coli strains stained green in color in the presence 
of MNPs but without exposure to AMF (Figure 3.13 A, B, E, F). The control group of 
bacterial cells in the absence of both MNPs and AMF also stained green in color (Figure 
3.14 A and B). These results further support the non-toxic nature of the nanoparticles. 
Several research groups obtained similar results for live/dead staining assay when 
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magnetic nanoparticles were used as antibacterial agents [25, 26, 36]. These results 
correlate with those obtained in CFU reduction assay wherein EC K99 and EC O157 
showed ~3-log reduction and ~1-log reduction in CFU/ml, respectively, after 120 minutes 
of AMF treatment in the presence of GM3-MNPs. 
 
Figure 3.14 Live/Dead Staining Assay using SYTO 9 and Propidium iodide dyes: A - EC K99 in the absence of MNPs 
and no AMF; B - EC O157 in the absence of MNPs and no AMF. Magnification - 400X, Scale bar - 100 µm. 
 
3.5 ATP Assay: 
The amount of ATP level present in any cell determines its metabolic state. In the 
presence of toxic materials/chemicals, the metabolic state of the cell can change and the 
intracellular ATP levels could drop because of toxicity. Higher levels of intracellular 
ATP levels indicate that the cell is metabolically active and their levels directly correlate 
to the actual number of bacterial cells present in the solution. Currently, several 
antibiotics available in the market exert their effects on targeting bacterial membrane 
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components to eradicate infections [37, 38]. To further demonstrate and explain the effect 
of AMF exposure on the biochemical metabolism of the inner cell membrane, an ATP 
assay based on luminescence was conducted to evaluate final ATP levels of EC K99 and 
EC O157 after exposing them to AMF for 120 minutes in the presence of different types 
of MNPs at their highest concentrations (650 µg Fe/ml). As seen in Figure 3.15 A, a 
substantial decrease in intracellular ATP levels of EC K99 (p<0.001) after 120 minutes of 
AMF treatment can be observed in the presence of GM3-MNPs only while EC K99 in the 
presence of PEO-MNPs with/without AMF did not show significant changes in ATP 
levels. In contrast, the intracellular levels of EC O157 were found to be slightly reduced 
both in the presence of PEO-MNPs or GM3-MNPs with AMF exposure (Figure 3.15 B). 
A similar decrease in ATP levels was reported in P. aeruginosa when they were 
subjected to magnetic induction in the presence of iron-oxide nanoparticles [26]. One 
possible explanation for reduced ATP levels in the presence of AMF exposure can be the 
decline in membrane potential of bacteria, which could lead to interruption in ATP 
synthesis mechanisms (e.g., reduced proton motive force), membrane depolarization and 
eventually cell-death [32, 39, 40]. 
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Figure 3.15 Intracellular ATP levels of bacterial strains in the presence of MNPs using BacTiter Glo. A - ATP levels of 
EC K99 after 120 minutes of AMF treatment in the presence of MNPs; B - ATP levels of EC O157 after 120 minutes 
of AMF treatment in the presence of MNPs. Data expressed as Mean ± SD (n = 3); Statistical Analysis - 2-Way 
Analysis of Variance (ANOVA). * p-value <0.05,  **  p-value <0.01, and *** p-value <0.001. 
It is worth noting that EC O157 when treated with AMF in the presence of PEO-
MNPs or GM3-MNPs resulting in similar limited level of cell damage, reductions in 
viable cells and intracellular ATPs. These results indicated that the changes are 
independent of the GM3 functional groups present on the surface of MNPs. The 
susceptibility of EC O157 to localized temperature changes due to proximity could be 
due to a lower thermal decimal reduction time (D-value) of EC O157 than that of EC K99 




Proof-of-concept multi-anchored glycoconjugate GM3-MNPs that have high 
affinity to adhesin of EC K99 were synthesized. The prepared nanoparticle system can 
specifically interact with adhesin molecules of EC K99 and cause agglutination through 
nanoparticle-bacteria complex. Applying AMF treatment to such complex caused 
significant reduction in viability of targeted bacteria EC K99 in both pure-culture and 
mixed-cultures settings due to possible highly localized temperature increase. Exposure 
to such conditions resulting in compromised membrane integrity of EC K99 as 
determined through TEM imaging and Live/Dead staining. Moreover, GM3-MNPs 
coupled with AMF resulted in significant decrease in the overall intra-cellular ATP levels 
of the bacterium. Hence, the unique multi-anchored nanoparticle system in the presence 
of AMF can be effectively used as novel non-antibiotic platform for local and selective 
inactivation of the target bacteria in biological systems without affecting the viability of 
nearby cells/tissues. In the event of gastro-intestinal (GI) tract infections caused by ETEC 
pathogens, administered antibiotics can disrupt/destroy beneficial gut micro-flora in 
addition to pathogens. It could cause various side effects in the human body along with 
giving rise to antibiotic-resistant bacterial strains. The presented system can find useful 
applications in treating such infections in animals and humans and in conditions when 
administered antibiotics, especially those of the last-line-of-defense drugs, fail to 
eradicate the infections due to drug-resistance. Future studies will involve optimization of 
particle parameters including nanoparticle core-size and polymer coatings, as well as a 
detailed investigation on the effects of field strength and frequency to maximize killing 
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rate of clinically relevant multi-drug resistant bacterial pathogens. Additionally, 
biocompatibility of our nanoparticle system will be evaluated in human cell-lines and 
small animal models. 
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Assessing the Biocompatibility of Multi-anchored Glycoconjugate 
Functionalized Magnetic Nanoparticles in Normal Human Colon Cell-
line CCD-18Co 
[Parts of this chapter are taken directly or adapted from work published in Advanced 
Functional Materials journal by Raval et al. (2017); DOI: 10.1002/adfm.201701473. 




In the last two decades, nanotechnology has evolved to be one of the most 
promising scientific areas, which have a huge potential to drastically change the facet of 
biomedical world in terms of its applicability. As a result, there has been a continuous 
rise in the amount of literature reported that deals with the application of nanomaterials to 
treat various human diseases [1, 2]. Application of nanomaterials in biomedical field, 
commonly referred to 'Nanomedicine', has attracted huge investments (in billions) in 
research & development funding both in the US and European counterparts. For example, 
the annual budget of National Nanotechnology Initiative (NNI) of US government grew 
exponentially from $0.5 billion in 2001 to $24 billion in 2017 [3, 4]. Some of the widely 
used nanoparticles for biomedical applications include gold nanoparticles, silver 
nanoparticles, magnetic nanoparticles, quantum dots, etc. These nanoparticles have been 
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used for targeted drug and gene delivery (e.g., delivery of anticancer drugs), as 
antibacterial agents, as vaccines, in various bio-imaging techniques like magnetic 
resonance imaging (MRI), positron emission tomography (PET) & computerized 
tomography (CT), and in diagnostics among several other applications [5-9].  Despite the 
rapid splurge in funding of nanoparticle research aimed for treating several diseases, not 
much success has been achieved in terms of their effective use in clinical settings [4, 10]. 
Currently, there exists a huge fundamental gap in translating the laboratory-based 
results of different nanoparticles that can certainly be used in bench-to-bedside scenarios. 
Some of the major factors that prevent their clinical use are difficulties in successful 
synthesis of nanoparticles that have consistent physical and chemical properties, reduced 
stability of nanoparticles in biological environment, poor understanding of the 
interactions which occurs between nanoparticles, biomolecules, and body fluids, and 
lastly the safety and biocompatibility of nanoparticles inside human body [11, 12]. 
Amongst all of the above stated issues, in this chapter, we will be mainly focusing on 
how surface functionalization of magnetic nanoparticles can affect its interaction with 
biological environment. Among various metallic nanoparticles, magnetic nanoparticles 
(MNPs), on account of their small size, unique magnetic properties and high degree of 
biocompatibility, have garnered major attention in nanomaterials research due to their 
multitude biomedical applications, which include but are not limited to targeted drug 
delivery, magnetic hyperthermia, magnetic resonance imaging, cell separation, cancer 
therapy, diagnostics and pathogen detection [13-15]. In fact, MNPs are already used 
clinically as MRI contrast agents for therapeutic purposes [6, 16]. Recent research efforts 
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have largely concentrated on manipulating the surface chemical properties of MNPs so as 
to render them high stability in biological rich environment. During the typical synthesis 
procedure, the resultant MNPs are generally found to be hydrophobic in nature and hence 
it is colloidically unstable in biological environment, thereby, not suitable in clinical 
applications [17, 18]. Making such MNPs hydrophilic is of prime importance in order to 
achieve chemically stable colloidal suspension of MNPs. For this purpose, surface 
coating of MNPs is essential and functionalizing the core of MNPs by robust 
monomeric/polymeric stabilizers typically does it. Also, these polymers should be 
biologically inert in nature so as to provide electrostatic and or stearic repulsion and 
'stealth' properties to MNPs in presence of protein-rich environment and at the same time 
they should be able to circulate in the body for prolonged time duration until they reach 
their targeted location without triggering body's immune response [19, 20].  
Some of the commonly employed monomeric agents that can easily bind to the 
core of MNPs include carboxylic acids, alcohols, sulfates, phosphates, and amines [18, 
21-23]. Polymeric stabilizers utilized for surface stabilization of MNPs usually include 
binding groups such as polyethylene glycol (PEG)/polyethylene oxide (PEO), alginate, 
dextran, poly vinyl alcohol (PVA), chitosan, etc. [24-27]. Extensive studies have been 
done on synthesized MNPs that has PEO polymer as the main stabilizing agent. PEO is 
one of the universally accepted polymers that have been approved by the FDA. Some of 
major advantages of attaching PEO onto nanoparticles, which make them extremely 
suitable for clinical applications, are improved stability of the entire nanoparticle system 
in biological environment, imparting 'stealth' properties to MNPs and extended blood 
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circulation time, amphiphilic in nature, soluble in water as well as in many other solvents, 
can act as carrier molecule in different pharmaceutical products and the ease of 
manipulating its surface chemistry for wide-spread use in biomedical applications [17, 
26, 28, 29]. However, in the presence of high salt & protein concentration, few of the 
above-mentioned binding groups tend to undergo desorption process and can be easily 
displaced from the surface of MNPs core (generally made up of iron-oxide). More 
specifically, anionic phosphates and silicates present in bodily fluids and also on the 
surface of several peptide molecules have high affinity towards iron-oxide core of MNPs 
and hence can lead to colloidal instability and rapid aggregation of MNPs [17]. In order 
to overcome this issue, recent studies have suggest that catechol-based anchor groups can 
inhibit non-specific interactions of other reactive groups towards the iron-oxide core and 
this has greatly improved the stability of MNPs in physiological fluids [30-34]. These 
catechol groups frequently use dopamine-based molecules that can tightly bind to metal 
oxide cores (especially Fe3O4), and can also be effortlessly attached to polymeric agents 
via different chemistry routes.   
Several studies have presented MNPs coated with appropriate polymer stabilizing 
agents to be highly biocompatible and biodegradable in in vitro and in vivo [9, 15, 35, 
36]. The main advantage of using MNPs for clinical applications is that, compared to 
other nanoparticles, MNPs can be metabolized and completely removed/excreted from 
the body through various systemic and cellular iron homeostasis pathways [37, 38]. 
However, it should be carefully noted that the biocompatibility of MNPs is highly 
dependent on multitude of factors like core size, final size of MNPs, surface chemistry of 
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the MNPs, adsorbed proteins on the surface of MNPs, given dosage, biodistribution, and 
final localization of MNPs in the body among several others [37, 39-41]. In spite of 
having excellent biocompatibility, numerous in vitro and in vivo studies have 
demonstrated differential toxicity of MNPs [24, 38, 41-43]. The different toxicity 
mechanisms observed in determining safe dosage levels of MNPs in cell-line studies 
include impaired mitochondrial function, cytotoxicity, cell apoptosis, DNA damage and 
genotoxicity, immunotoxicity, oxidative stress, disordered cell morphology, cytoskeleton 
damage, cell-membrane damage, etc. [11, 24, 25, 37, 44, 45]. Other factors that influence 
the toxicity levels of MNPs in in vitro conditions include type of cell-line, concentration 
of MNPs, incubation time, and cellular uptake [4, 46]. To date, the majority of the cell-
line toxicity studies of MNPs have been largely conducted in cancer cell-line models. 
Some of the commonly used ones are breast, colon, intestinal, lung, and brain cancer cell-
lines [5, 6, 47-49]. However, using such cancer cell-lines does not always provide 
reliable nanotoxicity evaluation of tested nanomaterials since these cell-lines may have 
been intentionally manipulated with to make them immortal [46, 50]. Also, cancer cells 
have higher proliferation rate, higher resilience to foreign objects, disorganized and leaky 
blood vessels, and altered cellular signaling pathways and therefore they do not correctly 
represent the physiological/biological state of normal cells [46, 51]. Hence, in-depth 
toxicological studies carried out in normal cell-lines or primary cells are warranted to 
fully comprehend and determine the possible toxicity mechanisms of MNPs before 
further testing is done in animal models. 
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Carbohydrates are important group of molecules that play vital role in numerous 
biological processes in mammalian systems. Some of the key processes modulated by 
carbohydrate molecules, include cell-cell communication, molecular signal transduction, 
cell growth and differentiation, apoptosis, inflammation and immune responses, tumor 
metastasis etc. [52-54]. Several of these carbohydrate molecules also serve as cell-surface 
receptors that can recognize viral/bacterial pathogens entering into the cells. Over the last 
two decades, numerous reports have utilized functionalized nanoparticles (e.g., gold 
nanoparticles, silver nanoparticles, diamond nanoparticles, magnetic nanoparticles, 
carbon nanotubes etc.) based on carbohydrate chemistry, which includes monosaccharide, 
disaccharides, oligosaccharides, and glycan/glycoconjugate molecules [55-58]. These 
studies have investigated the role of different carbohydrate molecules present on the 
surface of nanoparticles in studying multivalent carbohydrate-carbohydrate interactions, 
carbohydrate-lectin interactions for therapeutic purposes. Nanoparticles functionalized 
with carbohydrate molecules offer many advantages compared to their monovalent forms 
especially with regard to achieving high affinity constant (Ka) and increased binding 
enthalpy (ΔH) due to presence of multivalent interactions [59]. On account of their high 
surface/volume ratio, functionalizing numerous carbohydrate groups onto the surface of 
nanoparticles is fairly easy and it also drastically increases the biocompatibility of the 
entire nanoparticle system. Especially, MNPs having different physico-chemical 
properties and functionalized with carbohydrates have been frequently used in various 
biomedical applications such as targeted drug delivery, MRI imaging, pathogen 
 108 
detection, as vaccines, anti-adhesion therapies, bio-sensing applications, cancer 
treatment, and cell-surface receptor mimicking [55-57, 59].  
Few studies have described using nanoparticles functionalized with specific 
lectins and carbohydrates for targeted drug delivery to colon cells [60-62]. Of late, 
nanoparticles loaded with different drugs have been used as therapeutic agents for 
treating inflammatory bowel syndrome (IBS) [63, 64]. Most of these treatment regimens 
often involve localized and targeted drug release via orally ingested nanoparticles to the 
colon region of the gastrointestinal tract (GI tract). Such approach increased the overall 
efficacy of the drugs used in treating IBS by utilizing various nano-drug formulation 
strategies that enhanced the uptake of drug-loaded nanoparticles into the 
inflamed/diseased region of the colon. Frequently, in the case for disease diagnosis and 
evaluation of IBS, GI tract imaging is done via MRI and CT scan [65]. These imaging 
techniques often include MNPs as theragnostic agents, which can act both as MRI 
contrast and drug delivery agents. By utilizing nano-platform based imaging techniques, 
it is possible to monitor the drug-release kinetics of nanoparticles in the GI tract. Most of 
the in vitro studies that have been carried out till date to understand the cellular and 
molecular interactions of nanoparticles with intestinal cells regularly use Caco-2 cells 
(human colorectal adenocarcinoma) monolayers [66-69]. However, using Caco-2 cells 
for such studies do not accurately reflect the physiological conditions of normal colon 
cells. Even though PEG/PEO polymer used for stabilizing MNPs has been reported to 
have excellent biocompatibility in numerous cell-lines and animal studies, several 
research studies have deemed it to be toxic to cells [70-74]. Most of the in vitro cell-line 
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studies evaluating toxicity of PEO-coated nanoparticles typically do not expose the cells 
above 100-200µg/ml [37, 75]. However, it is important to understand the biological 
response of cells in presence of sub-lethal and lethal concentrations of nanoparticles. 
Depending on overall size, surface charge, polymer length and degree of grafting density 
on nanoparticle surface, PEO can show differential toxicity.  
Previous research work has shown that MNPs synthesized with dopamine-
anchored heterobifunctional PEO polymer (PEO-MNPs) and bio-functionalized with 
sialic-acid specific glycoconjugate moiety (Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp) (GM3-
MNPs) can be effectively used as targeted antibacterial agents against enterotoxigenic 
Escherichia coli, which is usually associated with gastroenteritis and can also trigger 
post-infectious IBS [59, 76]. In this chapter, we will be focusing on evaluating the 
biocompatibility of both PEO-MNPs and GM3-MNPs in normal human colon cell-line 
CCD18-Co. According to author's knowledge, this is a first study which encompasses 
different toxicity assays to better understand the biocompatibility of glycoconjugate 
functionalized MNPs in normal human colon cells. Understanding the interactions 
occurring between different MNPs and CCD18-Co cells will eventually help in 
determining the safe dosage levels of these MNPs to be effectively used as novel drug 






2. Experimental Section: 
Synthesis of Magnetite Nanoparticles: Magnetite nanoparticles were synthesized 
via thermal decomposition of an organometallic precursor in a high boiling point organic 
solvent [77]. Iron (III) acetylacetonate (Alfa Aesar, 99%) (1.074g) was combined in a 3-
neck round-bottom with oleic acid (Alfa Aesar, 90%) (15ml) serving as both the solvent 
and the stabilizing ligand. The vessel was initially purged with N2 after which flow was 
adjusted to 0.1 L/min ensuring an inert environment.  The vessel was then heated to 
350°C and left to react for 3 hours. At 3 hours, the reaction was quenched by removing it 
from heat, and left to cool under inert atmosphere. The resulting particles were dispersed 
in minimal hexanes and precipitated using a mixture of 3:1 ethanol (Fisher, Anhydrous) 
to acetone (Alfa Aesar, 99.5%) (x3). Particles were dispersed in toluene (VWR, 99.5%) 
and run through an organic based GPC column (Bio-rad S-X polystyrene beads) to 
further remove excess oleic acid ligand [78]. TEM and size analysis was then done on the 
particles to ensure size specificity. 
Synthesis of Alkyne-PEO-PAA-Dopamine [79]: Poly(ethylene oxide) (PEO) 
synthesis: Ethylene oxide (Sigma Aldrich, 99.9%) distilled into a high pressure Parr 
reactor. Na-benzylphenone still dried tetrahydrofuran (THF, EMD Millipore, 99.9%) was 
injected along with a predetermined amount of an anionic initiator potassium bistrimethyl 
silyl amide (Sigma Aldrich, 1M in THF). The reaction was allowed to run for 72 hours 
and was subsequently terminated by opening the reactor to atmosphere. The synthesized 
PEO was precipitated with diethyl ether (VWR, 99.9%) and washed (3x) by dispersing it 
in chloroform, precipitating the polymer, centrifuging it at 15,000 RCF for 10 minutes 
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and pouring off the residual supernatant. The PEO was then dried under vacuum 
overnight. HNMR was performed to calculate molecular weight as well as to confirm the 
presence of the protected amine end-group.  
Under dry N2 atmosphere, hetero-functional PEO and sodium hydride (Sigma 
Aldrich, 95%), in slight excess, were dissolved in dry THF. This was allowed to react for 
30 minutes before an excess of propargyl bromide (Sigma Aldrich, 80% in toluene) was 
added drop-wise to the solution over 15 minutes. Once all of the propargyl bromide was 
added, the solution was allowed to stir for 12 hours at room temperature. The polymer 
was then purified by dissolution in chloroform and precipitation with diethyl ether (x3) 
and dried under vacuum for 12 hours. HNMR was performed to confirm the presence of 
an alkyne. 
Deprotection of the trimethyl silyl group was done in 1M hydrochloric acid 
(VWR) in methanol (VWR, 99+%) and allowed to react for 4 hours. The polymer 
methanol solution was diluted with DI water and the deprotected PEO was extracted (3x) 
with 50ml chloroform from which it was precipitated with diethyl ether and dried under 
vacuum. HNMR was performed to confirm the loss of the trimethylsilyl group. 
Coupling of the PEO to the poly(acrylic acid) (PAA, Sigma Aldrich Mn=1,800) was done 
by dissolving both in dry N,N-dimethylformamide (DMF, Sigma Aldrich, 99.8%) in a 5:1 
ratio. To this 1.1 excess (N-(3-dimethylaminopropyl)-N’-ethylcarodiimide hydrochloride 
(EDC, TCI, 98%) as well as catalytic amounts of 4-(dimethylamino)pyridine (DMAP, 
Alfa Aesar, 99+%) were added. The solution was allowed to stir for 12 hours. The 
solution was filtered, further purified by dissolution in chloroform following precipitation 
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with diethyl ether (x3) and then dried under vacuum. HNMR was done to confirm PEO-
PAA coupling. 
Attachment of the anchor group: Dopamine hydrochloride (Alfa Aesar, 99%) was 
dissolved in DMF along with a 10% molar excess of triethylamine (Alfa Aesar, 99%) and 
allowed to stir for 30 minutes. In a separate round-bottom the PEO-PAA was dissolved in 
DMF along with EDC and catalytic amounts of DMAP. To this the dopamine 
hydrochloride solution was added and the combined solution was allowed to stir for 12 
hours. The solution was then filtered, purified by dissolution in chloroform then 
precipitated in diethyl ether. The final product was dried under vacuum and analyzed via 
HNMR and IR to confirm the presence of the catechol. 
Ligand Exchange [32]: Both magnetite nanoparticles as well as the PEO-PAA-
dopamine were suspended separately in 5ml of chloroform. The particles were at an 
approximate concentration of 3mg/ml of Fe and the polymer at approximately 40mg/ml. 
The polymer was then transferred to a scintillation vial capped with a septum and placed 
in a sonication bath. The bath was turned on and over the course of 15 minutes the 
magnetic nanoparticle solution was injected into the polymer solution. Once injection 
was finished, the combined solution was allowed to further sonicate for 15 minutes. The 
solution was then removed and put on a shaker table for 72 hours. The chloroform was 
then removed via rotary evaporator and further dried under vacuum. Deionized water (DI 
H2O) was then added and the vial was sonicated to help mediate suspension into the 
water. The water-based particles were then filtered through a 0.2-micron nylon filter to 
ensure large aggregates were not present. The solutions were then run through a GPC 
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column (Bio-Rad P polyacrylamide beads) to separate excess polymer from the water 
dispersible particles. 
Click Chemistry [80]: The Cu(I) catalyzed Huisgen 1,3-dipolar cyclo-addition 
between the terminal polymer alkyne and the azido-GM3 was done in the aqueous phase 
with the azido-GM3 being the limiting reagent. A 2 mol% solution of Cu(II) sulfate 
(Sigma Aldrich, 99%) was combined with equivalent molar amounts of the THPTA 
(synthesized according to Hong et al.)  Cu chelating ligand and let to react for 10 minutes 
[81]. This was then transferred into the aqueous alkyne-particle suspension and the azide-
GM3 was then added. After both additions a 10mol% aqueous solution of (+)-sodium L- 
ascorbate (Sigma Aldrich 98+%) was added to facilitate the reduction of Cu(II) to Cu(I). 
The click reactions were left at room temperature for 12 hours, and were then purified 
using size exclusion chromatography [78]. 
Dynamic Light Scattering (DLS) and Zeta Potential Measurements: DLS was 
performed on the PEO-coated and GM3-coated magnetic nanoparticles to determine their 
hydrodynamic radius. The nanoparticle suspensions were diluted in water and placed into 
a cuvette. Three readings were taken at 25°C using Malvern Zetasizer Nano ZS to 
determine the intensity average size distribution and z-average diameter. Zeta-potential 
measurements of these nanoparticle suspensions were also determined using the same 
instrument. The suspensions were diluted with water and added into zeta-cell and three 
measurements were taken at 25°C.  
Furthermore, 50µg/ml concentration of PEO-MNPs and GM3-MNPs were added 
in a cuvette and incubated at 37°C for different time intervals with Dulbecco's modified 
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eagle's medium (DMEM) supplemented without/with 10% fetal bovine serum (FBS) to 
investigate the stability of MNPs in protein and salt rich biological environment. After 
the incubation time, DLS (at 37°C) was performed on the above mentioned 
nanoparticles-cell culture suspension to check for any changes in their overall 
hydrodynamic diameters.  
Fourier Transform Infrared Spectroscopy (FTIR): FTIR microscopy was done 
using a Thermo-Nicolet Magna 550 FTIR spectrometer equipped with a Thermo-NicPlan 
FTIR microscope. 16 Scans were done for both the sample and the background. Samples 
were prepared by dropping a small amount of the water suspended sample on a 
germanium plate and left to dry under a heat lamp for 20 minutes. FTIR was done on the 
resulting films. 
Iron Concentration Determination: 50 µl of magnetite suspension was dissolved 
in concentrated HCl, reduced and complexed with 1,10-phenanthroline (Sigma-Aldrich, 
99%). UV-VIS was then performed to determine the amount of iron in the known volume 
[82, 83]. 
Culturing of CCD-18Co Cells: CCD-18Co human colon cells (normal) were 
procured from American Type Culture Collection (ATCC) and routinely grown on 50 
cm2 tissue-culture flask in the presence of Eagle’s Minimum Essential Medium (EMEM) 
at 37°C in a humidified atmosphere of 5% CO2 and 95% air. EMEM was supplemented 
with 2 mM L-Glutamine, non-essential amino acids, fetal bovine serum (final 
concentration - 10%), 100 UI/ml penicillin G, and 100µg/ml streptomycin. Fresh EMEM 
complete medium was added to growing cells every 2 days. For determining the 
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biocompatibility of MNPs, cells between passage generation of 12 and 25 were used. All 
the media chemicals, 96-well plates and culture flasks required for growing the cells were 
obtained from Corning, USA. 
Cytotoxicity of MNPs to CCD-18Co Cells [59]: The potential cytotoxicity of both 
PEO-MNPs and GM3-MNPs towards CCD-18Co cells was determined by performing 
MTS assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay, Promega, 
USA). For this assay, approximately 1.5 x 104 cells/well (100µl) were seeded (in 
triplicates) in transparent flat-bottom 96-well culture-plates at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air. After 24 hours, fresh growth medium containing 
varying concentrations (10µg/ml, 50µg/ml, 100µg/ml, 250µg/ml, and 500µg/ml of Fe) of 
PEO-MNPs and GM3-MNPs was added to the cells and the cells were incubated for 
further 24 and 48 hours. After the required incubation time period, cells were washed 
twice with sterile tissue-culture grade PBS. 100µl of fresh EMEM culture medium 
(without serum) was added to the wells and MTS assay was performed according to 
manufacturer’s protocol. Later, the plate was read at 490 nm optical density to measure 
the absorbance of the formazan product using a microplate reader (Thermo Scientific 
Multiskan™ FC) and percentage cell-viability rate of CCD-18Co cells in presence of 
MNPs was determined. 
Intracellular Adenosine Triphosphate (ATP) Levels of CCD-18Co Cells in 
Presence of MNPs [84, 85]: Intracellular ATP levels of CCD-18Co cells were measured 
in presence of both PEO-MNPs and GM3-MNPs to determine if their presence 
interrupted/inhibited ATP synthesis in the cells.  Approximately 1.5 x 104 cells/well 
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(100µl) were seeded (in triplicates) in white flat-bottom 96-well culture-plates at 37°C in 
a humidified atmosphere of 5% CO2 and 95% air. After 24 hours, fresh growth medium 
containing varying concentrations (10µg/ml, 50µg/ml, 100µg/ml, 250µg/ml, and 
500µg/ml of Fe) of PEO-MNPs and GM3-MNPs was added to the cells and the cells 
were incubated for further 24 and 48 hours. After the required incubation time period, 
cells were washed twice with sterile tissue-culture grade PBS. 100µl of fresh EMEM 
culture medium (without serum) was added to the wells and CellTiter-Glo® 2.0 assay 
(Promega, USA) was performed according to manufacturer's protocol with minor 
modification in incubation time period. After adding the CellTiter-Glo 2.0 reagent to the 
cells, the plate was gently mixed and later incubated at room temperature for 20 minutes. 
At the end of this assay, the plate was read in a micro-plate reader with luminescence 
capability (Synergy Hybrid H1, Biotek®) and the obtained results were expressed in 
relative luminescent units (RLUs).     
Cell Membrane Integrity of CCD-18Co cells in Presence of MNPs [24, 86]: 
Approximately 1.5 x 104 cells (600µl) were seeded (in duplicates) in 4-well chamber 
slide (Corning, USA) at 37°C in a humidified atmosphere of 5% CO2 and 95% air. After 
24 hours, fresh growth medium containing maximum concentration of PEO-MNPs and 
GM3-MNPs (i.e. 500µg/ml of Fe) were added to the cells and they were further incubated 
for 24 and 48 hours. Later, the cells were washed thrice with sterile tissue-culture grade 
PBS and finally the cells were re-suspended back in sterile tissue-culture grade PBS. 
Now, live/dead® viability assay (Invitrogen, USA) was performed to determine the extent 
of cell-membrane damage of CCD-18Co cells in presence of MNPs. Both the staining 
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dyes (Ethidium homodimer-1 and Calcein) were mixed together in a sterile 
microcentrifuge tube along with sterile tissue-culture grade PBS. The final concentrations 
of the dyes were 20µM and 10µM respectively when added to the chamber slides 
containing CCD-18Co cells. The chamber slide was then incubated at room temperature 
for 40 minutes. The stained cells were then observed under fluorescent microscope with 
appropriate fluorescent filter cubes (calcein - excitation/emission: 485/530 nm; ethidium 
homodimer-1 - excitation/emission: 530/645 nm) at 100X and 200X magnification. Later, 
the images obtained under different fluorescent filters were merged in ImageJ software 
(NIH, USA).  
Intracellular Glutathione (GSH) Levels of CCD-18Co Cells in Presence of 
MNPs [69, 87]: Approximately 1.5 x 104 cells/well (100µl) were seeded (in triplicates) in 
white flat-bottom 96-well culture-plates at 37°C in a humidified atmosphere of 5% CO2 
and 95% air. After 24 hours, fresh growth medium containing varying concentrations 
(10µg/ml, 50µg/ml, 100µg/ml, 250µg/ml, and 500µg/ml of Fe) of PEO-MNPs and GM3-
MNPs was added to the cells and cells were incubated for further 24 and 48 hours. After 
the required incubation time period, cells were washed twice with sterile tissue-culture 
grade PBS. Intracellular GSH levels were measured by utilizing GSH-Glo™ Glutathione 
assay kit (Promega, USA). All the subsequent steps in this experiment were done 
according to manufacturer's protocol with a minor modification in incubation times. After 
adding the GHS-Glo reagent to the cells, the plate was gently mixed and incubated at 
room temperature for 40 minutes. Subsequently, after adding luciferin detection reagent 
to the cells, the plate was further incubated for 20 minutes. At the end of this assay, the 
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plate was read in a micro-plate reader (Synergy Hybrid H1, Biotek®) and luminescence 
intensity of the each well obtained was expressed in relative luminescent units (RLUs).     
Intracellular Caspase 3/7 levels of CCD-18Co cells in Presence of MNPs [88, 
89]: Approximately 1.5 x 104 cells/well (100µl) were seeded (in triplicates) in white flat-
bottom 96-well culture-plates at 37°C in a humidified atmosphere of 5% CO2 and 95% 
air. After 24 hours, fresh growth medium containing varying concentrations (10µg/ml, 
50µg/ml, 100µg/ml, 250µg/ml, and 500µg/ml of Fe) of PEO-MNPs and GM3-MNPs was 
added to the cells and cells were incubated for further 24 and 48 hours. After the required 
incubation time period, intracellular caspase 3/7 protein levels were determined through 
Caspase-Glo® 3/7 assay kit (Promega, USA). The experiment was performed according 
to manufacturer's protocol and the plate was incubated for 2.5 hr at room temperature 
after adding the Caspase-Glo 3/7 reagent. Later, the plate was read in a micro-plate reader 
(Synergy Hybrid H1, Biotek®) and luminescence intensity of the each well obtained was 
expressed in relative luminescent units (RLUs).     
Statistical Analysis: All the statistical analysis was performed using GraphPad 
Prism software (V 7.0, CA, USA). All the experiments were done in triplicates and data 
are expressed as Mean±SD. Statistically significant differences between the groups were 
evaluated by performing ANOVA. Post hoc group comparisons were calculated through 
Tukey's multiple comparisons test. Results showing p-values of ≤0.05, <0.01, and 




3. Results and Discussion: 
3.1. Synthesis of GM3-MNPs 
Magnetite nanoparticles were synthesized using a one-pot thermal decomposition 
of iron (III) acetylacetonate and oleic acid [82, 90]. Particles had an average diameter of 
23.7 nm with a standard deviation of 1.55 nm (Figure 4.2 A and B). The moment vs. field 
(MvH) (Figure 4.3) measurement was done on the particles to confirm the super-
paramagnetic behavior of the MNPs. Polymer design was based on work by Stone et al. 
where a multi-anchored binding approach showed increased stability in comparison to 
polymer ligands with a single binding moiety (Figure 4.1) [79].  
 
Figure 4.1 Left: 1) Anionic ring opening of ethylene oxide, 2) alkyne functionalization with propargyl bromide, 3) 
deprotection of primary amine, 4) coupling of PEO to PAA, 5) coupling of dopamine hydrochloride to the PEO-PAA. 




Figure 4.2 Magnetite nanoparticles as synthesized before functionalization with PEO-PAA-dopamine polymer. A – 
Representative TEM image of the particles. B – Histogram depicting the particle size distribution. 
 
Figure 4.3 Moment vs. Field (MvH) loop showing the superparamagnetic behavior of the magnetite nanoparticles (Msat 
~ 53 emu/g Fe). 
 
In this work, however, the chosen catechol was not nitroDOPA but dopamine. 
HNMR of the polymer was used to confirm both the structure and molecular weight of 
the PEO-PAA-dopamine macromolecule (Figure 4.4).  By using the multi-anchored 
approach, the stability in salt and protein buffer solutions is retained even when using 
dopamine as the anchoring group [32, 33]. Hydrodynamic diameter and zeta potential of 
A B 
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the PEO-MNPs before and after click-coupling of GM3 are reported in Table 4.1.  
 
Figure 4.4 HNMR of the final PEO-PAA-dopamine - PAA backbone protons at 1.39 ppm - 1.08 ppm. Alkyne protons 
at 4.18 ppm and 2.42 ppm. PEO repeat protons at 3.62 ppm. Dopamine aromatic proton signal partially masked by the 
CDCl3 peak, with alkane protons showing up at 2.8 ppm. Reference was tetramethylsilane at ~0 ppm.  
 Hydrodynamic Diameter 







PEO-MNPs 78.8 -8.73 
GM3-MNPs 88.8 -7.68 
 
Table 4.1 Dynamic light scattering and zeta-potential measurements - Hydrodynamic diameter and zeta potential as 
measured by dynamic light scattering before and after GM3 conjugation. 
The increase in the hydrodynamic diameter indicates the GM3 glycoconjugate was 
successfully coupled to the PEO-MNPs. Attenuated total reflectance Fourier transformed 
infrared spectroscopy (ATR-FTIR) also confirmed the GM3 coupling went to completion 
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with the disappearance of the azide peak from GM3 at ~2110 cm-1 and the appearance of 
a broad alcohol peak in the GM3-MNPs spectrum from 3620-3170 cm-1 (Figure 4.5) [59]. 
 
 
Figure 4.5 FTIR spectra of particles before GM3 conjugation (A), GM3 molecule (B), and after conjugation (C). The 
lack of the azide peak in C at 2100 cm-1 indicates purification of unbound GM3 after conjugation was successful. 
 
The presence of biological medium has an important effect on the overall size 
diameter and surface charge of the synthesized MNPs. The presence of functional groups 
on the surface of MNPs also determines the extent to which it interacts with salts and 
proteins. DLS studies were conducted both on PEO-MNPs and GM3-MNPs over a period 
of 3 days to evaluate their overall stability in cell-culture medium DMEM in 
absence/presence of 10% FBS. As seen from table 4.2, the particle size of PEO-MNPs (in 
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water) instantly increased from 78.8 nm to 173.03 nm (more than doubled) within 5 
minutes of incubation in presence of DMEM. After 72 hr, the particle size still remained 
~170 nm. The presence of FBS in DMEM did not significantly change the overall 
diameter of PEO-MNPs during the entire experimental period. However, we did notice a 
slight reduction in size of PEO-MNPs in presence of DMEM+FBS. In contrast, GM3-
MNPs (in water) increased their size from 88.8 nm to 104 nm (an increase of ~18 nm) 
when mixed and incubated for 5 minutes in presence of DMEM. Here also the overall 
size of GM3-MNPs did not change drastically over 3 days incubation time-period in 
presence of DMEM. Interestingly, after mixing GM3-MNPs with media containing 
DMEM+FBS for 5 minutes, there was no major change in the diameter (88.8 nm to 91.14 
nm). However, after 24 hr and beyond, the size increased to ~110 nm in presence of 
DMEM+FBS. Several studies have reported the formation of 'protein-corona' (protein 
adsorption) layer on the surface of MNPs when incubated in presence of cell-culture 
medium containing high salt and protein concentrations [37, 91, 92]. It is due to this 
protein-corona formation that the overall size of the nanoparticles is increased. Moreover, 
extended period of protein-corona formation can also affect the colloidal stability of 
nanoparticle system in the biological media and eventually the nanoparticles tend to lose 
their colloidal stability and form aggregates due to corona formation.  
The presence of different types of chemical functional groups found on polymers 
and the length of the polymer itself plays an important role as to how and what kind of 
proteins interact with the nanoparticle surface and become adsorbed on it [4, 45]. In our 
results, we observed a rapid increase in size diameter of PEO-MNPs within 5 minutes of 
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incubation with DMEM and once the size was increased, it remained pretty consistent for 
the next 72 hr. Such kind of phenomenon can be credited to formation of thick layer of 
'hard protein-corona', which essentially represents an irreversible change in the amounts 
of proteins, which are getting adsorbed/released over a period of time on the surface of 
nanoparticles [93, 94]. Albumin and globulins are most dominant serum proteins found in 
any cell-culture medium [4]. Major ionic salts that are present in any cell-culture medium 
include sodium (Na+), potassium (K+), chloride (Cl-), and bicarbonate (HCO3-). The PEO-
PAA polymer that we used as multi-anchored stabilizing agent for PEO-MNPs have a lot 
of reactive alkyne groups on its surface that are free and can potentially interact with the 
above mentioned serum proteins and ionic salts present in DMEM. A study done by 
Ekkebus et al. showed that terminal alkyne groups could selectively react with cysteine 
amino acid via thiol-alkyne side chain reaction [95]. The size increase of PEO-MNPs 
when mixed with DMEM could be due to the chemical interactions taking place between 
the free alkyne groups present on our polymer chains with thiol end-group containing 
amino acids like cysteine and cystine. Moreover, several coenzymes and cofactors 
present in DMEM contain thiol groups, which can also interact with alkyne. The above-
mentioned chemical reactions taking place between alkyne and thiol-rich compounds 
might be one of the reasons for formation of protein-corona around PEO-MNPs in 
DMEM and thereby increasing its overall diameter size by more than 2-fold. In the case 
of GM3-MNPs, the PEO-PAA polymer with alkyne group underwent 'click reaction' to 
covalently attach GM3 molecule through alkyne-azide linkage. So, GM3-MNPs would 
have relatively less amount of free alkyne groups, which can interact with serum proteins 
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and ionic salts of DMEM and hence less amount of proteins would get adsorbed on its 
surface and forms a thin layer of protein-corona which would eventually increase the 
overall size of GM3-MNPs but only to a certain extent (increase of  ~18 nm). 
Furthermore, it is worthwhile to note that presence of multi-anchored DOPA group is 
also responsible for maintaining colloidal stability of MNPs in biological environment 
via intact stearic interactions. Recent work of Stone et al. (2015) suggested that multi-
anchored dopamine groups present on MNPs made them colloidically stable in FBS 
medium compared to mono-anchored groups that lost their stability by forming large 
aggregates having size diameter of >500 nm [34].  
Hydrodynamic Diameter Z. average (nm) of MNPs in Presence of Cell-Culture 














+ DMEM + 
10% FBS 
t = 5 min 78.8 nm 173.03 nm 167.03 nm 88.8 nm 104.00 nm 91.14 nm 
t = 24 hr 78.4 nm 171.97 nm 164.70 nm 88.6 nm 106.00 nm 106.00 nm 
t = 48 hr 78.1 nm 171.17 nm 165.83 nm 88.1 nm 106.80 nm 109.90 nm 
t = 72 hr 78.1 nm 172.50 nm 164.77 nm 88.3 nm 108.00 nm 110.30 nm 
 
Table 4.2 Dynamic light scattering measurements - Hydrodynamic diameter of MNPs as measured by dynamic light 
scattering in presence of cell-culture medium DMEM. 
 
The presence of nanomaterials in cell-lines is one of the many factors responsible 
for inducing toxicity in them. Different nanoparticles, when presented with direct contact 
to cells, can elicit cytotoxic responses inside mitochondria. One of the many in vitro 
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assays, which determine the damage done to mitochondria in presence of nanoparticles, is 
to quantify and measure the reductase/dehydrogenase enzymes activity inside the living 
mitochondria [39, 96]. MTS assay in one of the frequently employed cytotoxicity assay, 
which measures the amount of tetrazolium salt that is bio-reduced to formazan product by 
viable cells. This amount can then be detected colorimeterically and formazan produced 
is directly proportional to the number of living cells. The cytotoxicity of PEO-MNPs and 
GM3-MNPs to CCD-18Co cells was measured by CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay [59]. Increasing concentrations of both MNPs were added and 
the cells were incubated for 24 and 48 hr. As seen from figure 4.6 A, PEO-MNPs were 
found to be highly cytotoxic to CCD-18Co cells above 100µg/ml concentration after 24 
hr of exposure in a dose-dependent manner. <5% cell-viability was observed in the cells 
exposed to 500µg/ml concentration of PEO-MNPs at the end of 24 hr. Interestingly; 
GM3-MNPs did not show any significant cytotoxicity at all concentrations. In 
comparison to 24 hr time-period, PEO-MNPs showed significant cytotoxicity to the cells 
after 48 hr exposure even at 100µg/ml concentration (Figure 4.6 B). Above this 
concentration, <5% cell-viability of CCD-18Co cells was seen. To our surprise, cells 
exposed to GM3-MNPs for 48 hr did not show any significant cytotoxicity. Even the 
maximum concentration of 500µg/ml of GM3-MNPs showed >90% viability rate. PEO 
polymer attached to nanoparticle surface is generally found to be biocompatible both in 
in vitro and in vivo settings [25, 26, 28]. However, there have been few reports of toxicity 
of PEO coated nanoparticles. In a recent study conducted by Escamilla-Rivera et al., 
MNPs coated with PEG were found to have 50% cell-viability at 100µg/ml concentration 
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after 48 hr exposure to THP-1 macrophages [97]. Also, the presence of PAA group on the 
polymer has been described to have significant toxicity in animal models [71, 98, 99]. It 
should be also noted that cell-viability rate also depends on the length of PEO tails 
present on the surface of MNPs as reported by Hafeli et al. [100]. Their study showed 
that by increasing tail length of PEO polymer (from 0.75 kDa to 15 kDa), cell-viability 
rate of various human cell-lines also increased. Also, the presence of 
carbohydrate/glycoconjugate molecules on MNPs have been reported to have no 
significant cytotoxicity to different cell-lines the results of which were similar to what we 
observed [101-103].  
 
   
Figure 4.6 Cell-viability cytotoxicity MTS assay: a) CCD-18Co cells exposed to varying concentrations of PEO-MNPs 
for 24 hr; b) CCD-18Co cells exposed to varying concentrations of GM3-MNPs for 48 hr. Data is expressed as Mean ± 
SD (n=3); Statistical analysis – Analysis of Variance (ANOVA); * p-value <0.05,  ** p-value <0.01, and *** p-value 
<0.001 
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The amount of ATP level present in any cell determines its metabolic state. In the 
presence of any toxic materials/chemicals, the metabolic state of the cell will change and 
the intracellular ATP levels can drop if there is any significant cytotoxicity to the cells. 
Higher levels of intracellular ATP commonly indicates that the cell is metabolically 
active and their level directly correlate to the actual number of living cells. Numerous 
research studies have reported a significant decrease in intracellular ATP levels of cells in 
presence of different types of nanoparticles [104-106]. To further understand the inherent 
cytotoxic mechanisms of MNPs on the inner cell membrane biochemical cycles taking 
place inside mitochondria, we measured the intracellular ATP levels of CCD-18Co cells 
based on luminescent assay. The cells were incubated with different concentrations of 
PEO-MNPs and GM3-MNPs for 24 and 48 hr. As seen from figure 4.7 A and B, the ATP 
levels of the cells started to decrease substantially when exposed to PEO-MNPs above 
100µg/ml concentration. More than 90% reduction in the ATP levels was observed for 
250µg/ml and 500µg/ml concentrations of PEO-MNPs. In comparison, cells exposed to 
GM3-MNPs for 24 hr did not show any significant decrease in ATP levels at all 
concentrations. When the exposure time was increased to 48 hr, cells in presence of PEO-
MNPs showed a rapid decline in intracellular ATP levels beginning from 100µg/ml 
concentration (Figure 4.7 B). At concentrations above 100µg/ml, a significant reduction 
(>95%) in ATP levels was seen in presence of PEO-MNPs. Several reports have 
suggested that the kind of polymer coating and size of MNPs could play an important 
role in maintaining ATP levels inside the cells. In one such study, MNPs coated with 
different polymers like DEAE, chitosan and PEI exhibited variation in its cytotoxic 
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response to human brain microvascular endothelial cell-line with PEI-MNPs showing 
maximum cytotoxicity [107]. In another study, MNPs functionalized with starch were 
incubated with murine macrophage cell-line for 48 hr and the authors observed a drastic 
decrease in ATP levels of the cells [108]. However, presence of GM3-MNPs to the CCD-
18Co cells did show a slight decrease (not significant) in ATP levels at concentrations 
above 250µg/ml, thereby, proving that GM3-MNPs do not cause any detrimental toxic 
effects on the overall functioning of ATP synthesis mechanisms inside mitochondria in 
CCD-1Co cells. These results prove that PEO-MNPs can possibly interfere with the ATP 
synthesis pathways inside the mitochondrial membrane, which can cause reduction in 
proton motive force and membrane depolarization.  
   
Figure 4.7 Intracellular ATP levels of CCD-18Co cells in the presence of MNPs using CellTiter Glo 2.0 assay. A) ATP 
levels of cells exposed to PEO-MNPs at increasing concentrations for 24 hr; B) ATP levels of cells exposed to GM3-
MNPs at increasing concentrations for 48 hr. Data is expressed as Mean ± SD (n=3); Statistical analysis – Analysis of 
Variance (ANOVA); * p-value <0.05,  ** p-value <0.01, and *** p-value <0.001 
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Next, we evaluated the potential toxicity of MNPs to CCD-18Co cells by 
performing membrane integrity assay. It is one of the commonly employed in vitro assays 
that determine the extent of membrane damage of mammalian cells when exposed to 
various nanomaterials [75, 96]. Most of these assays utilize a mixture of fluorescent dyes 
that can interact with specific enzymes present inside the cells depending on their ability 
to enter the cell. In our study, we exposed the cells only to highest concentration of 
MNPs (500µg/ml) based on the preliminary cytotoxicity results that we observed. After 
the predetermined incubation time-period, live/dead viability assay was done in presence 
of 2 different fluorescent dyes, calcein AM and ethidium homodimer-1. Calcein AM is a 
cell-permeable dye, which is non-fluorescent to begin with. Once inside the living cell, 
various intracellular esterases break down this dye and it is retained inside the cells that 
have intact membrane and can now emit intensely green fluorescence. Contrary, ethidium 
homodimer-1 dye cannot enter the live cell that has intact membrane. Those cells whose 
cell-membrane integrity has been compromised only take it up and once inside these 
damaged cells, it can brightly emit red fluorescence. As seen from figure 4.8 C, CCD-
18Co cells exposed to PEO-MNPs after 24 hr showed a distinct change in their 
morphology and structure compared to control cells, which showed perfect slender and 
elongated fibrils (Figure 4.8 A). The cells were found to be clumped together in small 
irregular round/oval shapes. There was partial membrane damage to the cells as evident 
from limited red fluorescence. After 48 hr exposure, majority of the cells exposed to 
PEO-MNPs suffered extensive membrane damage (as seen by intense red fluorescence) 
and the cells also shrunk in size (Figure 4.8 D). We also observed extensive cell-
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detachment in CCD-18Co cells in presence of PEO-MNPs. Such cell features are 
indicative of necrosis/ apoptosis. In comparison, cells incubated with 500 µg/ml of GM3-
MNPs for 24 and 48 hr did not show any visible cell-membrane damage (Figure 4.8 E 
and F). More than 90% viability has seen in these cells. However, we did notice a small 
change in the overall size and arrangement of the cells. Compared to control group, cells 
exposed to GM3-MNPs had smaller fibrils. Also, their overall size dimensions (in terms 
of length and width) slightly reduced. They were also found to be growing at further 
distance from each other and there was hardly any overlapping of cell fibrils with each 
other referred to cell retraction. One possible explanation for such morphological change 
in cells in presence of MNPs might have to do with maintaining of cytoskeleton 
structures that includes actin and tubulin filaments. Both these structures are essential for 
proper growth and maintenance of cells as they directly take part in cell-cell 
communication, transport of nutrients and other vital organelles. Nonetheless, the change 
in cell morphology in presence of MNPs is something that has been already investigated 
previously. Few research studies have reported that MNPs functionalized with dextran, 
citric acid and PEG can effectively disrupt the overall cytoskeleton arrangement in 
different cell-lines through destruction of actin and microtubules through cell uptake [86, 
109, 110]. Also, at high concentrations of MNPs (500 µg/ml and 1000 µg/ml), the overall 
length and diameter of murine neural progenitor cells and primary human blood 
outgrowth endothelial cells were found to be condensed and these cells also showed 
retraction properties (growing but tend to repeal from each other) during their growth 
cycle which is similar to what we observed in CCD-18Co cells exposed to GM3-MNPs 
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[111]. It also reduced the expression of focal adhesion kinase (FAK) protein, which is 
suggested to have damaging repercussions on kinase signaling pathways that maintains 
the cytoskeleton structures. Such disruptions in cytoskeleton pathways can activate pro-
apoptosis signaling pathways in the cells, which can lead to cell-death. Thus, the results 
of our live/dead staining assay suggests that PEO-MNPs can possibly interfere and 
destroy cell cytoskeleton structures that can stall the regular cell cycle and cause cell-
death. Whereas, the presence of GM3 molecule on MNPs can potentially prevent such 
drastic cytoskeleton toxicity of CCD-18Co cells.  
 













Figure 4.8 Live/Dead staining assay using calcein AM and ethidium homodimer-1 dyes. CCD-18Co cells were 
incubated in presence of PEO-MNPs and GM3-MNPs for 24 and 48 hr (Concentration - 500µg/ml). Live cells appear 
green in color and dead cells appear red in color. All the images were merged together for both green and red channel 
filters of the microscope. A, B - control cells (no MNPs); C, D - cells exposed to PEO-MNPs; E, F - cells exposed to 
GM3-MNPs. Magnification: 100X; Scale bar - 100µm. 
 
It is known that the amount of reactive oxygen species in the cellular environment 
gives an indication of the oxidative stress levels. Glutathione (GSH) is an important and 
powerful antioxidant present in the mammalian cell. It normally exists in oxidized dimer 
form (GSSH). However, when the cell is experiencing oxidative stress due to presence of 
reactive oxygen species, free radicals, and toxic metal ions, GSSH is converted into its 
reduced monomeric form, GSH, which is an indicator of cellular oxidative stress that can 
lead to cell death or apoptosis [112, 113]. There have been numerous reports of increased 
oxidative stress in cells exposed/treated with different kinds of nanomaterials especially 
MNPs [114-116]. So, in order to evaluate whether CCD-18Co cells are undergoing 
cellular oxidative stress in presence of MNPs, we carried out GSH-glo assay to check for 
any changes in the overall GSH levels. At the end of 24 hr exposure to PEO-MNPs, the 
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GSH levels in the cells decreased drastically at concentrations of 250µg/ml and 500µg/ml 
(Figure 4.9 A). In the case of GM3-MNPs, cells lowered their overall GSH counts only at 
highest concentration of 500µg/ml. Compared to 24 hr, cells exposed to 48 hr of PEO-
MNPs and GM3-MNPs exhibited concentration-dependent decrease in GSH levels 
starting from 50µg/ml concentration (Figure 4.9 B). Interestingly, even the lowest 
concentration of 10µg/ml was sufficient enough to cause a substantial decline in cellular 
GSH levels. The overall reduction in GSH levels obtained in this experiment was not 
something unexpected. Numerous works have examined the effect of MNPs in disturbing 
the overall mechanisms of antioxidant pathways in cells [117-119]. The most common in 
vitro and in vivo toxicity of MNPs develop due to production of reactive oxygen species 
(ROS), which include singlet oxygen, hydrogen peroxide, hydroxyl radicals and 
superoxide anions [114, 120]. MNPs are likely to be taken up by the cells via different 
endocytic pathways depending on their size and surface chemistry [121]. Once inside the 
cells, MNPs are typically degraded in the lysosomes into ferrous (Fe2+) ions due to their 
low pH environment. These Fe2+ ions could potentially enter the mitochondrial 
membrane system through membrane depolarization and interact with different enzymes 
of the electron transport system especially with NADPH oxidase, oxygen and hydrogen 
peroxide producing ferric ions (Fe3+) and highly reactive hydroxyl radicals through 
Fenton chemistry [38, 122]. High levels of ROS species can deteriorate the cellular levels 
of GSH thereby causing oxidative stress. A study conducted by Watanabe et al. reported 
that exposing MNPs to human alveolar epithelial cells caused DNA damage, increased 
ROS production and reduced GSH levels even at low concentration of 10µg/ml, which is 
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similar to what we observed [123]. Similarly, significant increase in ROS levels and 
simultaneous reduction in GSH levels was observed in human breast cancer cells when 
exposed to MNPs. Here too, the authors described these effects to be time and 
concentration-dependent [124]. Based on these results, we can aptly deduce that both 
type of MNPs systems used in our experiments are responsible for generating increased 
ROS levels along with reducing intracellular GSH levels in CCD-18Co cells. Further 
studies needs to be conducted to decide the exact levels of several intracellular ROS (e.g., 
hydroxyl ions, hydrogen peroxide, singlet oxygen etc.) that are getting boosted due to 
presence of MNPs to fully elucidate the role of ROS in causing cellular toxicity in 
presence of MNPs. 
   
Figure 4.9 Intracellular Glutathione (GSH) levels of CCD-18Co cells in the presence of MNPs using GSH-Glo assay. 
A) GSH levels of cells exposed to PEO-MNPs at increasing concentrations for 24 hr; B) GSH levels of cells exposed to 
GM3-MNPs at increasing concentrations for 48 hr. Data is expressed as Mean ± SD (n=3); Statistical analysis – 
Analysis of Variance (ANOVA); * p-value <0.05,  ** p-value <0.01, and *** p-value <0.001 
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The presence of nanomaterials in biological system has been shown to induce 
apoptosis in cells by activating various cell-death signaling pathways [43, 125]. In order 
to determine whether CCD18-Co cells are showing any apoptotic activity in presence of 
MNPs, we quantitatively measured the levels of caspase3 and caspase7 proteins. These 
caspase proteins belong to cysteine-aspartic acid protease (caspase) family. This family 
also includes other caspase proteins like caspase6, caspase8, caspase9, and caspase10 that 
play a central role in activation of cell apoptosis [126, 127]. Upon detecting a major 
change in the normal biochemical processes occurring inside the mitochondria, different 
signaling pathways are activated, which can trigger the activation of caspase family 
proteins. One of the last proteins of caspase family to get activated before the cell 
inadvertently goes into cell-death stage is caspase3 [128]. So, we performed caspase-glo 
3/7 assay on CCD18-Co cells exposed to MNPs to check if their presence has activated 
the caspase signaling pathways leading to apoptosis. On incubating the cells with PEO-
MNPs, we did not see any significant change in the levels of caspase3/7 proteins up to 
250µg/ml concentrations (Figure 4.10 A). However, cells exposed to 500µg/ml PEO-
MNPs showed a substantial increase in activity of caspase3/7 proteins, which suggests 
that the cells might be undergoing apoptosis. In comparison, cells incubated with GM3-
MNPs for 24 hr maintained similar caspase3/7 levels at all concentrations. When the 
exposure time of MNPs to cells was increased to 48 hr, cells incubated with both 
250µg/ml and 500µg/ml concentrations of PEO-MNPs showed a notable rise in 
caspase3/7 levels (Figure 4.10 B). This proves that even at concentration of 250µg/ml of 
PEO-MNPs, the cells may be experiencing apoptosis. Surprisingly, when were incubated 
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with GM3-MNPs for 48 hr, we did not observe a significant change in the caspase levels 
until the concentration was 500µg/ml. These results suggests that both PEO-MNPs and 
GM3-MNPs are able to activate caspase signaling events in CCD-18CO cells only when 
presented with highest concentrations of MNPs. However, it seems that the exposure time 
does play a critical role in induction of apoptosis as the overall caspase levels were 
elevated at 48 hr compared to 24 hr. Similar kind of results were obtained in several 
research findings that showed time-dependent increase in caspase protein levels in 
presence of MNPs [89]. The results obtained in this experiment are a little different (in 
terms of concentration-dependent rise in caspase levels) than what has been reported 
earlier. In one of the study done by Yin et al, the caspase3 levels in rat cerebellum cells 
showed a dose-dependent increasing trend when exposed to silver nanoparticles [129]. In 
another study, the size and surface functionalization of polystyrene latex nanoparticles 
played a significant part in initiating caspase dependent apoptotic pathways in human 
alveolar epithelial cells [130]. They noticed that cells exposed to 100 nm amine-coated 
nanoparticles had significantly higher levels of caspase proteins compared to those 
exposed to 50 nm size nanoparticles and also to carboxyl-coated nanoparticles. Hence, 
based on our results of caspase3/7 assay, it seems that the surface chemistry and exposure 
time are important parameters to consider when using MNPs for therapeutic applications. 
The levels of other apoptotic proteins needs to be determined in order to completely 
understand the if cellular toxicity mechanism in presence of MNPs is indeed due to 
activation of apoptosis signaling pathways. 
 138 
   
Figure 4.10 Intracellular caspase3/7 activity levels in CCD-18Co cells exposed to MNPs using Caspase-Glo 3/7 assay. 
A) Caspase3/7 levels of cells exposed to PEO-MNPs at increasing concentrations for 24 hr; B) Caspase3/7 levels of 
cells exposed to GM3-MNPs at increasing concentrations for 48 hr. Data is expressed as Mean ± SD (n=3); Statistical 
analysis – Analysis of Variance (ANOVA); * p-value <0.05,  ** p-value <0.01, and *** p-value <0.001 
 
Special Discussion: In this study, we have investigated and compared 
biocompatibility of PEO-MNPs with GM3-MNPs in normal human colon cell-line CCD-
18Co. The main difference in terms of chemical functionality between PEO-MNPs and 
GM3-MNPs was the presence of glycoconjugate molecule GM3 on the surface of GM3-
MNPs. As mentioned earlier, the type of surface functional groups present on MNPs 
plays an important role in regulating overall biocompatibility of the nanoparticle system 
both in in vitro and in vivo settings. Other factors that also play their part in imparting 
nanoparticle biocompatibility include surface charge, size, kind of polymer used, the 
extent to which it can form protein-corona in cell-culture medium, concentration of 
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nanoparticles, type of cells interacting with nanoparticles etc. [92, 94]. In order to check 
if MNPs were able to form protein-corona in protein and salt-rich biological medium, 
DLS studies were performed and it showed that PEO-MNPs significantly increased their 
overall size diameter. This increase can be attributed to formation of thick layer of 
protein-corona on the surface of nanoparticles. More specifically, the free alkyne group 
present on our heterobifunctional PEO polymer can potentially interact with various 
thiolated amino acids present in the cell-culture medium DMEM and due to this different 
protein molecules can bind to the surface of PEO-MNPs forming the corona and thereby 
increasing the size and possibly even altering the charge of nanoparticles [94, 95]. In 
contrast, there was only marginal diameter increase (~18 nm) for GM3-MNPs when 
mixed with DMEM. These results suggest that carbohydrate glycoconjugate coated 
MNPs can possibly act as drug-delivery agents as they do not significantly interact with 
the serum proteins, which would help in retaining its original physico-chemical 
properties. However, further detailed studies involving spectroscopic techniques needs to 
be done in order to fully identify the proteins interacting with MNPs and understand these 
mechanisms as the formation of protein-corona can potentially determine the nanoparticle 
uptake into the cells that would ultimately regulate cellular processes (Figure 4.11).   
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Figure 4.11 Formation of protein-corona on the surface of nanoparticles a) Formation of protein-corona on the 
nanoparticle surface depending on the physico-chemical properties of the initial material and b) Impact of protein-
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corona on structural and functional properties of protein molecules interacting with biological medium. Reprinted from 
[11] - Reproduced with permission from Nature Publishing Group. 
 
Over the last decade, numerous studies have expressed grave concern regarding 
the biocompatibility of engineered nanoparticles that are being extensively used for 
biomedical applications (e.g., gold nanoparticles, silver nanoparticles, magnetic 
nanoparticles etc.). These nanoparticles have been found to significantly affect the 
molecular machinery of the cells at different levels. Since nanoparticles have large 
surface area, even a minute change in their physico-chemical properties can have drastic 
effect on the way it interacts with cells. Among different factors responsible for these 
changes, the chemical properties and presence of surface chemical groups tend to 
outweigh all the other factors. The kind of chemical groups can potentially dictate if the 
nanoparticles have the ability to alter the electron accepting/donating mechanisms 
occurring inside the cells. Currently, the best possible explanatory model in determining 
the toxicological effects of engineered nanoparticles relies heavily on the generation of 
ROS [114, 120]. Among different type of nanoparticles, MNPs have been known to 
produce ROS when exposed to mammalian cells [114-116]. It is this very property that 
has made MNPs to be used for targeted drug delivery for cancer therapy in clinical use. 
MNPs are able to enter the cells via endocytosis and once inside, they can freely interact 
with lysosomes or endosomes and in this process they can increase ROS levels via 
Fenton reaction in the cells putting them under increased oxidative stress environment 
[114, 122]. In normal metabolic state, the ROS levels are usually found to be low in the 
cells. To counteract them, different antioxidant enzymes (catalase, superoxide dismutase, 
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etc.) and glutathione are produced by the cells. However, when ROS levels are increased 
significantly, the GSH levels and antioxidant enzyme levels are reduced and the cell 
experiences increased oxidative stress. In our experiments too, both PEO-MNPs and 
GM3-MNPs decreased intracellular GSH levels of CCD-18Co cell indicative of increased 
oxidative stress. Depending on the amount of oxidative stress, different response 
elements in the cells are activated. For example, at low level of oxidative stress, 
transcription factor Nrf-2 gets activated which in turn increases the production of various 
antioxidant enzymes which would typically restore the redox balance in the cells [120]. 
However, when the cells are experiencing high level of oxidative stress, numerous cell-
signaling pathways related to inflammation and cytotoxicity are activated (e.g., mitogen-
activated protein kinase (MAPK), nuclear factor κB (NF-κB), AP-1). Higher ROS levels 
also interfere with the electron transport system (ETS) of mitochondria that could 
potentially reduce the activity of ATP synthase pump leading to membrane 
depolarization and lipid peroxidation, which can induce irreversible damage of plasma 
membrane. These pathways can also activate pro-apoptosis factors in the cells, which 
would eventually result in activation of caspase molecules leading to apoptosis (Figure 
4.12). Thus, in order to get an overall view of the ROS induced toxicity of our MNPs, 
elaborate studies on cellular uptake of MNPs, gene expression changes taking place in 
mitochondria (those involved in ETS chain), and extensive analysis of inflammatory 
factors involved in these mechanisms are warranted in in vitro conditions before these 
MNPs can be used for toxicity testing in animal models. Moreover, as MNPs are clinical 
used in magnetically triggered drug delivery through alternate magnetic fields, complete 
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Figure 4.12 Possible mechanisms of nanoparticle toxicity induced by increased ROS levels. Reprinted from [131] - 
Reproduced with permission from Elsevier Ltd. 
 
4. Conclusion: 
We successfully synthesized multi-anchored glycoconjugate functionalized GM3-
MNPs based on 'click-chemistry' platform that are stabilized with heterobifunctional 
PEO-PAA polymer having dopamine molecules as robust anchoring agents to the iron-
oxide core. The above-mentioned GM3-MNPs were fully characterized through 
numerous techniques and their stability in cell-culture medium DMEM was investigated. 
In the presence of high salt and high protein environment of DMEM, MNPs were able to 
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form protein-corona layer on their surface within rapid time duration. Size diameter of 
PEO-MNPs increased significantly compared to GM3-MNPs suggesting formation of 
thick protein-corona layer. PEO-MNPs are able to cause strong decrease in cell-viability 
of CCD-18Co cells at concentrations above 100 µg/ml whereas GM3-MNPs did not show 
any cytotoxic effects on the cells. Also, intracellular ATP levels of CCD-18Co were 
significantly diminished in presence of PEO-MNPs but not GM3-MNPs indicative of 
interference in the activity of ATP synthase pump. PEO-MNPs also compromised the 
membrane integrity of the cells possibly due to apoptosis/necrosis; however, cells 
exposed to GM3-MNPs showed significantly different cell morphology but no membrane 
damage which indicates subtle changes in cytoskeleton arrangement of the cells. Also, 
presence of PEO-MNPs and GM3-MNPs to the cells resulted in substantial decrease in 
the intracellular GSH levels in a time and concentration-dependent manner that clearly 
denotes existence of increased oxidative stress via formation of reactive oxygen species. 
Finally, we also determined if MNPs were able to induce apoptosis in normal colon cells 
by means of measuring the activity of caspase proteins. The levels of caspase3 and 
caspase7 proteins were found to be remarkably elevated in the cells in presence of PEO-
MNPs at higher concentrations, which was dependent on exposure time. Thus, based on 
the results that we obtained, it can be appropriate to assume that reduction of GSH due to 
increase in ROS levels and increased production of caspase3/7 proteins leading to 
apoptosis are few of the prominent factors responsible for triggering cellular toxicity in 
CCD-18Co cells in presence of PEO-MNPs. Some of the important nanoparticle 
synthesis parameters that directly affect toxic potential of MNPs and which warrants 
 145 
further in-depth studies include controlling the amount of PEO-PAA polymer groups that 
are being grafted onto the surface of MNPs as excessive free groups can interact with 
protein molecules altering the physico-chemical properties of MNPs, effect of post-
synthesis purification steps once the polymer is attached to the core of nanoparticle as 
chemical residues can also contribute to overall toxicity of MNPs. It is also important to 
mention here that since presence of glycoconjugate molecules on MNPs renders them 
relatively biocompatible, efforts should be made to increase the general efficiency of 
'click chemistry' reactions so that more glycoconjugate molecules are being attached to 
PEO-PAA polymer. Furthermore, investigation of immunotoxicity of MNPs is necessary 
as colon cells can trigger inflammatory response signaling pathways (e.g., nuclear factor 
κB (NF-κB), mitogen-activated protein kinase (MAPK)) in presence of MNPs, which can 
also lead to apoptosis. As we observed reduction in GSH levels of colon cells in presence 
of MNPs implying increased ROS generation, gene expression studies of ROS gene 
cluster would be valuable to explain the exact underlying mechanisms of increased 
oxidative stress that could also lead to apoptosis. Also, by attaching proper antioxidant 
chemicals/drugs to GM3-MNPs, they can be effectively used for targeted drug-delivery 
to colon cells remotely via magnetothermal drug release mechanisms in presence of 
alternate magnetic fields for therapeutic applications in treating infections caused during 
post-IBS.  
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Functionalized MNPs are currently one of the most commonly used nanomaterials in 
biomedical settings. Among different functional groups, MNPs having carbohydrate 
molecules attached to them have shown excellent biocompatibility in both in vitro and in 
vivo conditions. This dissertation work mainly focuses on developing proof-of-concept 
MNPs functionalized with specific sialic-acid based carbohydrate glycoconjugate 
molecule (Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp) (GM3-MNPs) and evaluating their 
interaction with enterotoxigenic E. coli strain EC K99.  These functionalized MNPs were 
synthesized by using special heterobifunctional PEO polymer comprising of dopamine 
molecules on one end and free alkyne groups on other end on which the GM3 molecule is 
attached via 'click chemistry' linkage. Specific interactions occurred between EC K99 and 
GM3-MNPs, which resulted in formation of aggregates of bacteria-nanoparticle complex 
as described in chapter 2. These results show that it is possible to create bacteria-specific 
multifunctional MNPs based on carbohydrate molecules that can find useful applications 
in rapid detection (ID system) of pathogens in biological samples.  
Later, in chapter 3, we evaluated the practicability of using GM3-MNPs developed on 
multi-anchored PEO-PAA dopamine platform for targeted killing of EC K99 in presence 
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of AMF. High degree of clinically significant specific in vitro bacterial killing (in both 
pure culture and mixed culture environment) was seen in EC K99 in presence of AMF 
possibly due to MagMED phenomenon and destruction of bacterial cell membrane. These 
results are pivotal since bacterial infections occurring in GI tract has heterogeneous 
environment i.e. presence of beneficial gut bacteria and using antibiotics for treating such 
infections would give rise to potential drug-resistant bacteria along with destroying the 
beneficial micro-flora. Future studies are warranted to test the effectiveness of AMF 
treatment in multi-drug resistant bacteria e.g., MRSA, carbapenem-resistant 
enterobacteriaceae group. Several important parameters like core-size of MNPs, polymer 
length, concentration of MNPs, magnetic field strength and applied frequency of AMF 
should be fine-tuned to improve the efficacy of treatment regimen in both in vitro and in 
vivo conditions. Once these factors are established, MNPs and AMF together would act 
as novel non-antibiotic agents for treating clinically relevant bacterial infections, thereby,  
eliminating the need of using antibiotics and diminishing the rise of drug-resistant 
bacteria. 
Different strategies have been employed to impart colloidal stability to MNPs in 
biological environment. The type of polymer used in stabilizing MNPs plays an 
important role in this regard. The presence of chemical functional group on surface of 
MNPs would define how it interacts with serum proteins and mammalian cell in in vitro 
setting, which would then determine its biocompatibility. Thus, finally in chapter 4, 
biocompatibility studies were undertaken to figure out the toxicity profile of MNPs 
developed on multi-anchored PEO-PAA dopamine platform. GM3-MNPs were able to 
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maintain their overall colloidal stability in protein-rich environment as they formed 
limited 'protein-corona'. They were also found to be fairly biocompatible (other than 
reducing GSH levels) compared to PEO-MNPs when exposed to normal colon cells 
CCD-18Co. This shows that presence of carbohydrate groups on MNPs surface can 
potentially impart biocompatibility. Nonetheless, extensive toxicity studies in animal 
models are necessitated for these carbohydrates functionalized MNPs. By carefully 
controlling different parameters of MNPs synthesis like size of MNPs, post-synthesis 
purification techniques, and efficient ligand-exchange reactions, it is possible to create 
MNPs functionalized with carbohydrate groups that are fully biocompatible and can be 
used in therapeutic applications. 
The results obtained in this work suggest that carbohydrate glycoconjugate functionalized 
MNPs have great potential to be effectively used in clinical settings as multifunctional 
theragnostics agents for e.g., simultaneous detection, isolation & destruction of targeted 
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